Meet Ashish Kamat, M.D.

Ashish M. Kamat, M.D., MBBS
Department of Urology, Division of Surgery
About Dr. Kamat
Ashish M. Kamat, MD, MBBS is an Endowed Professor of Urologic Oncology (Surgery) and Cancer Research at University of Texas MD Anderson Cancer Center. He is also President of the International Bladder Cancer Group (IBCG) and International Bladder Cancer Network (IBCN). He is Associate Editor for European Urology Oncology, Editor for the UroToday Bladder Cancer Center of Excellence, directed the MDACC Urologic Oncology Fellowship from 2005-2016, and is an alumnus of the AUA Leadership Program
Dr. Kamat is recognized internationally as an expert in urologic oncology with an emphasis on bladder cancer, immunotherapy, organ-sparing and minimally invasive techniques. Dr. Kamat maintains an active research portfolio in this area with a focus on efforts to develop novel therapies and diagnostics, and identifying predictors of response to therapy (e.g. intravesical immunotherapy), as a first step towards personalized cancer therapeutics. He has led several national and international studies, which have been reported in high impact journals. Dr. Kamat is an exceptional educator and as Program Director grew the Urologic Oncology Fellowship into the premier program in the US. In 2016, a scholarly endowment was created in honor of Dr Kamat, the "Wayne B. Duddlesten Professorship in Honor of Dr Ashish Kamat" for his work in Cancer Research and Education at MD Anderson. Dr Kamat has over 325 publications, is listed in'Who's Who in Medicine' and'Best Doctors in America', and has won the'Compassionate Doctor Award' from patient groups.
Additionally, Dr. Kamat is on grant review panels of national and international study sections, serves in an advisory capacity to various organizations, such as the National Cancer Institute's (NCI) Bladder Cancer Task Force (BCTF), Society of Immunotherapy for Cancer (SITC); and as an AUA International Faculty. He is a member of the AUA Guidelines Panel for Bladder Cancer.
Present Title & Affiliation
Primary Appointment
Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX
Wayne B. Duddleston Sr. Professorship in honor of Dr. Ashish Kamat, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston
Research Interests
Immunotherapy, Personalized Therapeutics, Organ Conservation, Novel therapies, Stem Cell Biology
Education & Training
Degree-Granting Education
1994 | Seth G. S. Medical College & King Edward Memorial Hospital, University of Bombay, Bombay, IND, MBBS (MD), Medicine, Surgery |
1988 | University of Bombay - Jai Hind College, Bombay, IND, HSC, Biologic Sciences |
Postgraduate Training
2001-2003 | Fellowship, Urologic Oncology, MD Anderson Cancer Center, Houston, TX |
Board Certifications
2015 | American Board of Urology |
Experience & Service
Academic Appointments
Associate Professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, Houston, TX, 2008 - 2014
Assistant Professor, Department of Urology and Cancer Biology, Division of Surgery, The University of Texas M. D. Anderson Cancer Center, Houston, TX, 2003 - 2008
Administrative Appointments/Responsibilities
Fellowship Program Director, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2016
Residency Program Director, Department of Urology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2005 - 2014
Other Appointments/Responsibilities
Chair, Cancer Immunotherapy Guidelines (CIG) Committee, Society of Immunotherapy for Cancer (SITC), Milwaukee, WI, 2019 - 2021
Member, Board of Directors, The Société Internationale d’Urologie (SIU), Montreal (Quebec), 2019 - Present
Member, Board of Directors, Albert Institute for Bladder Cancer Care and Research, Kansas City, KS, 2018 - Present
Research Council Member (SCSREP), American Urological Association, Linthicum, MD, 2017 - 2025
President, International Bladder Cancer Group (IBCG), Delaware, 2016 - Present
Associate Cancer Center Director, Reliance Foundation HN Hospital, Mumbai, 2016 - Present
JU Editorial Board (SCSREP), American Urological Association, Linthicum, MD, 2016 - 2023
Chair, Bladder Cancer Task Force, Society of Immunotherapy for Cancer (SITC), Milwaukee, WI, 2014 - Present
President (US), International Bladder Cancer Network (IBCN), Hamburg, 2014 - Present
State Representative (Texas), South Central Section of AUA, Houston, 2011 - Present
Member, Young Urologist Committee, American Urological Association, Linthicum, MD, 2009 - 2013
Member, Practice Guidelines Committee, American Urological Association, Linthicum, MD, 2009 - 2011
Member, Board of Directors, South Central Section AUA, Schaumburg, IL, 2008 - Present
Medical Director, Bladder Cancer Support Group, MDACC SPORE, Houston, TX, 2007 - 2014
Associate Member, Center for Biomedical Engineering, Houston, TX, 2003 - 2007
Institutional Committee Activities
Member, International Advisory Board, 2017 - Present
Member, Africa Committee, 2016 - Present
Member, Promotion and Tenure Committee, 2015 - 2018
Member, GMEC Budget Committee, 2013 - 2016
Member/Advisor, Surgical Services Advisory Committee, 2011 - Present
Mentor, MD Anderson Cancer Center Speed Mentoring, 2011 - 2011
Co-Director, GU SPORE Career Development Program, 2008 - 2009
Member, MD Anderson India Steering Committee, 2008 - Present
Member, Clinical Effectiveness Committee, 2007 - 2008
Member, POE Operating Room Safety Council, 2007 - 2018
Urology Representative, Faculty Senate, 2006 - 2008
Member, Division of Surgery Education/Training Committee, 2004 - 2005
Member, OR Committee, 2003 - Present
Member, Graduate Medical Education Committee, 2002 - 2016
Consultantships
Special Expert, National Cancer Institute (NCI) Bladder Cancer Task Force, Bethesda, MD, 2014 - 2020
Consultant, National Cancer Institute (NCI) Bladder Cancer Task Force, Bethesda, MD, 2010 - Present
Scientific Advisory Board, National Bladder Cancer Think Tank, Bethesda, MD, 2007 - Present
Honors & Awards
2020 | Inaugural Clawater Professor, UTMB |
2017 | Inaugural Lecturer - Albert Lectureship in Bladder Cancer, Kansas University |
2016 | Faculty Educator Award, MD Anderson Cancer Center |
2016 | Emil J Freireich Award for Excellence in Education (Nominee) |
2016 | Outstanding Program Director Award (Nominee), MD Anderson Cancer Center GME |
2016 | Wayne B. Duddleston Sr. Professorship in honor of Dr. Ashish Kamat |
2014 | Robert M. Chamberlain Distinguished Mentor Award Nominee, MD Anderson Cancer Center |
2014 | Chair, Bladder Cancer Task Force, Society of Immunotherapy for Bladder Cancer, SITC (Society of Immunotherapy for Bladder Cancer) |
2013 | Top Reviewer in Urology, AUA |
2012 | Outstanding Reviewer in 2012 Award, The Journal of Urology |
2012 | Mentor Award Nominee, MD Anderson Cancer Center |
2011 | Compassionate Doctor Award, Patient Recognition |
2008 | AUA Leadership Program Award, American Urological Association |
2008 | Best Doctors in America |
2008 | Board of Directors, South Central Section of the American Urological Association |
2007 | Excellent Reviewer Award, UT MD Anderson Cancer Center |
2007 | Fellow, American College of Surgeons (FACS), American College of Surgeons |
2005 | Who's Who in America |
2004 | Faculty Award, AACR |
2003 | Bladder SPORE Developmental Research Program Award, NCI |
2002 | Scholar in Training Award, American Association for Cancer Research |
2001 | Outstanding Laparoendoscopist, Society of Laparoendoscopic Surgeons |
2000 | First Prize, American College of Surgeons |
2000 | Best Published Papers in "Urology", AUA |
1999 | Scholars in Urology (National), Pfizer |
1999 | First Prize, American College of Surgeons |
1999 | First Prize, West Virginia University |
1999 | Second prize, University of Pittsburgh |
1997 | Outstanding/Best Paper Presentation, West Virginia University |
1992 | Dr. L. H. Hiranandani Scholarship in Otorhinolaryngology, University of Bombay |
1991 | Gold Medal Performance, University of Bombay |
1991 | Manorama Vijayrat Hazarat Prize for Highest Cumulative Score, University of Bombay |
1991 | Distinctions in Forensic Medicine and Medical Jurisprudence, Pharmacology, Microbiology, Biochemistry and Preventive and Social Medicine, University of Bombay |
1991 | Shamdasani Foundation Scholarship for Standing First in University, University of Bombay |
1991 | Seth Khimchand Amulakh Prize for Excellence in Pharmacology, University of Bombay |
Professional Memberships
Selected Publications
Peer-Reviewed Articles
- Hensley PJ, Bree KK, Brooks N, Matulay J, Li R, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Time Interval from Transurethral Resection of Bladder Tumor to BCG Induction Does Not Impact Therapeutic Response. BJU Int. e-Pub 2021. PMID: 33783950.
- van der Kwast T, Liedberg F, Black PC, Kamat A, van Rhijn BWG, Algaba F, Berman DM, Hartmann A, Lopez-Beltran A, Samaratunga H, Varma M, Cheng L. International Society of Urological Pathology Expert Opinion on Grading of Urothelial Carcinoma. Eur Urol Focus. e-Pub 2021. PMID: 33771477.
- Vlahou A, Hallinan D, Apweiler R, Argiles A, Beige J, Benigni A, Bischoff R, Black PC, Boehm F, Céraline J, Chrousos GP, Delles C, Evenepoel P, Fridolin I, Glorieux G, van Gool AJ, Heidegger I, Ioannidis JPA, Jankowski J, Jankowski V, Jeronimo C, Kamat AM, Masereeuw R, Mayer G, Mischak H, Ortiz A, Remuzzi G, Rossing P, Schanstra JP, Schmitz-Dräger BJ, Spasovski G, Staessen JA, Stamatialis D, Stenvinkel P, Wanner C, Williams SB, Zannad F, Zoccali C, Vanholder R. Data Sharing Under the General Data Protection Regulation: Time to Harmonize Law and Research Ethics?. Hypertension:HYPERTENSIONAHA12016340. e-Pub 2021. PMID: 33583200.
- Baack Kukreja J, Li R, Narayan VM, Lim A, Seif MA, Wang X, Kamat A, Dinney CP, Navai N. Oncologic equipoise between robotic and open radical cystectomy. J Endourol. e-Pub 2021. PMID: 33619985.
- Feldman AS, Kulkarni GS, Bivalacqua TJ, Black PC, Delacroix S, Lerner SP, Kamat AM, Kassouf W. Surgical challenges and considerations in Tri-modal therapy for muscle invasive bladder cancer. Urol Oncol. e-Pub 2021. PMID: 33642229.
- Jazzar U, Bergerot CD, Shan Y, Wallis CJ, Freedland SJ, Kamat AM, Tyler DS, Baillargeon J, Kuo YF, Klaassen Z, Williams SB. Use of Psychotropic Drugs Among Older Patients with Bladder Cancer in the United States. Psychooncology. e-Pub 2021. PMID: 33507622.
- Matulay JT, Li R, Hensley PJ, Brooks NA, Narayan VM, Grossman HB, Navai N, Dinney CPN, Kamat AM. Contemporary Outcomes of Patients with Non-Muscle Invasive Bladder Cancer Treated with BCG Therapy: Implications for Clinical Trial Design. J Urol:101097JU0000000000001633. e-Pub 2021. PMID: 33502236.
- Bree KK, Hensley PJ, Brooks NA, Matulay J, Li R, Nogueras Gonzalez GM, Navai N, Grossman HB, Matin SF, Dinney CP, Kamat AM. Impact of upper tract urothelial carcinoma on response to bcg in patients with non-muscle invasive bladder cancer. BJU Int. e-Pub 2021. PMID: 33484074.
- Yang M, Georgieva MV, Bocharova I, Vembusubramanian M, Qian K, Guo A, Kamat AM. The Impact of Progression on Healthcare Resource Utilization and Costs Among Patients with High-Grade Non-Muscle Invasive Bladder Cancer After Bacillus Calmette-Guérin Therapy: A Retrospective SEER-Medicare Analysis. Adv Ther. e-Pub 2021. PMID: 33543424.
- Kukreja JB, Seif MA, Mery MW, Incalcaterra JR, Kamat AM, Dinney CP, Shah JB, Feeley TW, Navai N. Utilizing time-driven activity-based costing to determine open radical cystectomy and ileal conduit surgical episode cost drivers. Urol Oncol. e-Pub 2020. PMID: 33308972.
- Brooks NA, Kokorovic A, Xiao L, Matulay JT, Li R, Ranasinghe WKB, Nagaraju S, Shen Y, Gao J, Navai N, Dinney CPN, Grossman HB, Kamat AM. The obesity paradox: defining the impact of body mass index and diabetes mellitus for patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin. BJU Int. e-Pub 2020. PMID: 33210440.
- Koti M, Ingersoll MA, Gupta S, Lam CM, Li X, Kamat AM, Black PC, Siemens DR. Sex Differences in Bladder Cancer Immunobiology and Outcomes: A Collaborative Review with Implications for Treatment. Eur Urol Oncol 3(5):622-630, 2020. e-Pub 2020. PMID: 32967818.
- Gao J, Navai N, Alhalabi O, Siefker-Radtke A, Campbell MT, Tidwell RS, Guo CC, Kamat AM, Matin SF, Araujo JC, Shah AY, Msaouel P, Corn P, Wang J, Papadopoulos JN, Yadav SS, Blando JM, Duan F, Basu S, Liu W, Shen Y, Zhang Y, Macaluso MD, Wang Y, Chen J, Zhang J, Futreal A, Dinney C, Allison JP, Goswami S, Sharma P. Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma. Nat Med. e-Pub 2020. PMID: 33046869.
- Li R, Sundi D, Zhang J, Kim Y, Sylvester RJ, Spiess PE, Poch MA, Sexton WJ, Black PC, McKiernan JM, Steinberg GD, Kamat AM, Gilbert SM. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin. Eur Urol 78(3):387-399, 2020. e-Pub 2020. PMID: 32143924.
- Bagheri I, Shan Y, Klaassen Z, Kamat AM, Konety B, Mehta HB, Baillargeon JG, Srinivas S, Tyler DS, Swanson TA, Kaul S, Hollenbeck BK, Williams SB. Comparing Costs of Radical Versus Partial Cystectomy for Patients Diagnosed With Localized Muscle-Invasive Bladder Cancer: Understanding the Value of Surgical Care. Urology. e-Pub 2020. PMID: 32980405.
- Teoh JY, Huang J, Ko WY, Lok V, Choi P, Ng CF, Sengupta S, Mostafid H, Kamat AM, Black PC, Shariat S, Babjuk M, Wong MC. Global Trends of Bladder Cancer Incidence and Mortality, and Their Associations with Tobacco Use and Gross Domestic Product Per Capita. Eur Urol. e-Pub 2020. PMID: 32972792.
- Necchi A, Gallina A, Dyrskjøt L, Roupret M, Kamat AM, Spiess PE, Grivas P, Gibb EA, Briganti A, Montorsi F. Converging Roads to Early Bladder Cancer. Eur Urol 78(2):127-130, 2020. e-Pub 2020. PMID: 32197887.
- Li R, Gilbert SM, Kamat AM. Unraveling the Mechanism of the Antitumor Activity of Bacillus Calmette-Guérin. Eur Urol. e-Pub 2020. PMID: 32861573.
- Lobo N, Shariat SF, Guo CC, Fernandez MI, Kassouf W, Choudhury A, Gao J, Williams SB, Galsky MD, Taylor JA, Roupret M, Kamat AM. What Is the Significance of Variant Histology in Urothelial Carcinoma?. Eur Urol Focus 6(4):653-663, 2020. e-Pub 2019. PMID: 31530497.
- Hwang MJ, Kamat AM, Dinney CP, Czerniak B, Guo CC. Bladder Cancer Involving Smooth Muscle of Indeterminate Type or Muscularis Mucosae in Transurethral Biopsy Specimens. Am J Clin Pathol 154(2):208-214, 2020. e-Pub 2020. PMID: 32253420.
- Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Van Der Kwast T, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, De Visschere PJL, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, Oyen WJG, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Willemse PM, Williams A, Zigeuner R, Horwich A. Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]. Eur Urol 78(1):e48-e50, 2020. e-Pub 2020. PMID: 32446863.
- Wallis CJD, Novara G, Marandino L, Bex A, Kamat AM, Karnes RJ, Morgan TM, Mottet N, Gillessen S, Bossi A, Roupret M, Powles T, Necchi A, Catto JWF, Klaassen Z. Risks from Deferring Treatment for Genitourinary Cancers: A Collaborative Review to Aid Triage and Management During the COVID-19 Pandemic. Eur Urol 78(1):29-42, 2020. e-Pub 2020. PMID: 32414626.
- O'Connor E, Teh J, Kamat AM, Lawrentschuk N. Bacillus Calmette Guérin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?. Future Oncol 16(19):1323-1325, 2020. e-Pub 2020. PMID: 32406253.
- Brooks NA, Narayan V, Hegarty PK, Zafirakis H, Han XY, Kamat AM. The role of the urologist, BCG vaccine administration, and SARS-CoV-2: An overview. BJUI Compass 1(3):87-92, 2020. e-Pub 2020. PMID: 32835353.
- Westerman ME, Kokorovic A, Wang XS, Lim A, Garcia-Gonzalez A, Seif M, Wang R, Kamat AM, Dinney CPN, Navai N. Radical Cystectomy and Perioperative Sexual Function: A Cross-Sectional Analysis. J Sex Med. e-Pub 2020. PMID: 32713807.
- Kamat AM, Lerner SP, O'Donnell M, Georgieva MV, Yang M, Inman BA, Kassouf W, Boorjian SA, Tyson MD, Kulkarni GS, Chang SS, Konety BR, Svatek RS, Balar A, Witjes JA. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis. Eur Urol Oncol 3(3):318-340, 2020. e-Pub 2020. PMID: 32201133.
- Mostafid H, Babjuk M, Bochner B, Lerner SP, Witjes F, Palou J, Roupret M, Shariat S, Gontero P, van Rhijn B, Zigeuner R, Sylvester R, Comperat E, Burger M, Malavaud B, Soloway M, Williams S, Black P, Daneshmand S, Steinberg G, Brausi M, Catto J, Kamat AM. Transurethral Resection of Bladder Tumour: The Neglected Procedure in the Technology Race in Bladder Cancer. Eur Urol 77(6):669-670, 2020. e-Pub 2020. PMID: 32192815.
- Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MY, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA. Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy of Non-muscle Invasive Bladder Cancer. J Urol 203(5):101097JU0000000000000688, 2020. e-Pub 2019. PMID: 31821066.
- Matulay JT, Tabayoyong W, Duplisea JJ, Chang C, Daneshmand S, Gore JL, Holzbeierlein JM, Karsh LI, Kim SP, Konety BR, Li R, McKiernan JM, Messing EM, Steinberg GD, Williams SB, Kamat AM. Variability in adherence to guidelines based management of nonmuscle invasive bladder cancer among Society of Urologic Oncology (SUO) members. Urol Oncol. e-Pub 2020. PMID: 32430255.
- Brooks N, Nagaraju S, Matulay J, Han XY, Kamat AM. Bacillus Calmette-Guérin Retains Clinically Relevant Viability for up to 72 Hours After Reconstitution: Potential Implications for Clinical Practice in Times of Shortage. Eur Urol Oncol. e-Pub 2020. PMID: 32475716.
- Kamat AM, Gontero P, Palou J. How Should I Manage a Patient with Tumor Recurrence Despite Adequate Bacille Calmette-Guérin?. Eur Urol Oncol 3(2):252-257, 2020. e-Pub 2019. PMID: 31307960.
- Williams SB, Black PC, Dyrskjøt L, Seiler R, Schmitz-Dräger B, Nawroth R, Todenhöfer T, Kamat AM, Goebell PJ. Re: Aurélie Kamoun, Aurélien de Reyniès, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2019.09.006: A Statement from the International Bladder Cancer Network. Eur Urol 77(4):e105-e106, 2020. e-Pub 2019. PMID: 31787429.
- Matulay JT, Soloway M, Witjes JA, Buckley R, Persad R, Lamm DL, Boehle A, Palou J, Colombel M, Brausi M, Kamat AM. Risk Adapted Management of Low-Grade Bladder Tumors: Recommendations from the International Bladder Cancer Group. BJU Int 125(4):497-505, 2020. e-Pub 2020. PMID: 31950596.
- Kamat AM, Shore N, Hahn N, Alanee S, Nishiyama H, Shariat S, Nam K, Kapadia E, Frenkl T, Steinberg G. KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC. Future Oncol 16(10):507-516, 2020. e-Pub 2020. PMID: 32162533.
- Hegarty PK, Sfakianos JP, Giannarini G, DiNardo AR, Kamat AM. COVID-19 and Bacillus Calmette-Guérin: What is the Link?. Eur Urol Oncol, 2020. e-Pub 2020. PMID: 32327396.
- Jazzar U, Shan Y, Klaassen Z, Freedland SJ, Kamat AM, Raji MA, Masel T, Tyler DS, Baillargeon J, Kuo YF, Mehta HB, Bergerot CD, Williams SB. Impact of Alzheimer's disease and related dementia diagnosis following treatment for bladder cancer. J Geriatr Oncol, 2020. e-Pub 2020. PMID: 32354675.
- Narayan VM, Seif MA, Lim AH, Li R, Matulay JT, Kukreja JB, Qiao W, Hwang H, Shah JB, Pisters L, Kamat AM, Dinney C, Navai N. Radical cystectomy in women: Impact of the robot-assisted versus open approach on surgical outcomes. Urol Oncol 38(4):247-254, 2020. e-Pub 2020. PMID: 31953001.
- Liem EIML, Oddens JR, Vernooij RWM, Li R, Kamat A, Dinney CP, Mengual L, Alcaraz A, Izquierdo L, Savic S, Thalmann GN, Bubendorf L, Sylvester RJ, de Reijke TM. The Role of Fluorescence in Situ Hybridization for Predicting Recurrence after Adjuvant Bacillus Calmette-Guérin in Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer Patients: A Systematic Review and Meta-Analysis of Individual Patient Data. J Urol 203(2):101097JU0000000000000566, 2020. e-Pub 2019. PMID: 31549936.
- Li R, Kamat AM. Predictors of Response to Intravesical Therapy. Urol Clin North Am 47(1):23-33, 2020. PMID: 31757297.
- Witjes JA, Babjuk M, Bellmunt J, Bruins HM, De Reijke TM, De Santis M, Gillessen S, James N, Maclennan S, Palou J, Powles T, Ribal MJ, Shariat SF, Der Kwast TV, Xylinas E, Agarwal N, Arends T, Bamias A, Birtle A, Black PC, Bochner BH, Bolla M, Boormans JL, Bossi A, Briganti A, Brummelhuis I, Burger M, Castellano D, Cathomas R, Chiti A, Choudhury A, Compérat E, Crabb S, Culine S, De Bari B, De Blok W, J L De Visschere P, Decaestecker K, Dimitropoulos K, Dominguez-Escrig JL, Fanti S, Fonteyne V, Frydenberg M, Futterer JJ, Gakis G, Geavlete B, Gontero P, Grubmüller B, Hafeez S, Hansel DE, Hartmann A, Hayne D, Henry AM, Hernandez V, Herr H, Herrmann K, Hoskin P, Huguet J, Jereczek-Fossa BA, Jones R, Kamat AM, Khoo V, Kiltie AE, Krege S, Ladoire S, Lara PC, Leliveld A, Linares-Espinós E, Løgager V, Lorch A, Loriot Y, Meijer R, Mir MC, Moschini M, Mostafid H, Müller AC, Müller CR, N'Dow J, Necchi A, Neuzillet Y, Oddens JR, Oldenburg J, Osanto S, J G Oyen W, Pacheco-Figueiredo L, Pappot H, Patel MI, Pieters BR, Plass K, Remzi M, Retz M, Richenberg J, Rink M, Roghmann F, Rosenberg JE, Rouprêt M, Rouvière O, Salembier C, Salminen A, Sargos P, Sengupta S, Sherif A, Smeenk RJ, Smits A, Stenzl A, Thalmann GN, Tombal B, Turkbey B, Lauridsen SV, Valdagni R, Van Der Heijden AG, Van Poppel H, Vartolomei MD, Veskimäe E, Vilaseca A, Rivera FAV, Wiegel T, Wiklund P, Williams A, Zigeuner R, Horwich A. EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort†: Under the Auspices of the EAU-ESMO Guidelines Committees. Eur Urol 77(2):223-250, 2020. e-Pub 2019. PMID: 31753752.
- Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ. Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG Unresponsive Trials. Clin Cancer Res 26(4):882-891, 2020. e-Pub 2019. PMID: 31712383.
- Li R, Kukreja JEB, Seif MA, Petros FG, Campbell MT, Nguyen JV, González GMN, Kamat AM, Pisters LL, Dinney CP, Navai N. The role of metastatic burden in cytoreductive/consolidative radical cystectomy. World J Urol 37(12):2691-2698, 2019. e-Pub 2019. PMID: 30864005.
- Peyton CC, Chipollini J, Azizi M, Kamat AM, Gilbert SM, Spiess PE. Updates on the use of intravesical therapies for non-muscle invasive bladder cancer: how, when and what. World J Urol 37(10):2017-2029, 2019. e-Pub 2018. PMID: 30535583.
- Pignot G, Loriot Y, Kamat AM, Shariat SF, Plimack ER. Effect of Immunotherapy on Local Treatment of Genitourinary Malignancies. Eur Urol Oncol 2(4):355-364, 2019. e-Pub 2019. PMID: 31277773.
- Matulay JT, Woldu SL, Lim A, Narayan VM, Li G, Kamat AM, Anderson CB. The impact of squamous histology on survival in patients with muscle-invasive bladder cancer. Urol Oncol 37(6):353.e17-353.e24, 2019. e-Pub 2019. PMID: 30704959.
- Williams SB, Shan Y, Ray-Zack MD, Hudgins HK, Jazzar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB. Comparison of Costs of Radical Cystectomy vs Trimodal Therapy for Patients With Localized Muscle-Invasive Bladder Cancer. JAMA Surg:e191629, 2019. e-Pub 2019. PMID: 31166593.
- Li R, Metcalfe MJ, Tabayoyong WB, Guo CC, Nogueras González GM, Navai N, Grossman HB, Dinney CP, Kamat AM. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign. Eur Urol Oncol 2(3):286-293, 2019. e-Pub 2018. PMID: 31200843.
- Flannery K, Boyd M, Black-Shinn J, Robert N, Kamat AM. Outcomes in patients with metastatic bladder cancer in the USA: a retrospective electronic medical record study. Future Oncol 15(12):1323-1334, 2019. e-Pub 2019. PMID: 30942088.
- Boormans JL, Zwarthoff EC, Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. New horizons in bladder cancer research. Urol Oncol. e-Pub 2019. PMID: 30852032.
- Williams SB, Hudgins HK, Ray-Zack MD, Chamie K, Smaldone MC, Boorjian SA, Daneshmand S, Black PC, Kamat AM, Goebell PJ, Seiler R, Schmitz-Drager B, Nawroth R, Baillargeon J, Klaassen Z, Kulkarni GS, Kim SP, Lee EK, Holzbeierlein JM, Hollenbeck BK, Gore JL. Systematic Review of Factors Associated with the Utilization of Radical Cystectomy for Bladder Cancer. Eur Urol Oncol 2(2):119-125, 2019. e-Pub 2018. PMID: 31017086.
- Williams SB, Kamat AM, Mehta HB. Utility of Bladder-Sparing Therapy vs Radical Cystectomy for Muscle-Invasive Bladder Cancer-Reply. JAMA Surg 154(2):186, 2019. e-Pub 2018. PMID: 30476959.
- Matulay JT, Narayan VM, Kamat AM. Clinical and Genomic Considerations for Variant Histology in Bladder Cancer. Curr Oncol Rep 21(3):23, 2019. e-Pub 2019. PMID: 30806832.
- Fernández MI, Brausi M, Clark PE, Cookson MS, Grossman HB, Khochikar M, Kiemeney LA, Malavaud B, Sanchez-Salas R, Soloway MS, Svatek RS, Vikram R, Vrieling A, Kamat AM. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD-SIU joint consultation on bladder cancer. World J Urol 37(1):3-13, 2019. e-Pub 2018. PMID: 30105454.
- Li R, Tabayoyong WB, Guo CC, González GMN, Navai N, Grossman HB, Dinney CP, Kamat AM. Prognostic Implication of the United States Food and Drug Administration-defined BCG-unresponsive Disease. Eur Urol 75(1):8-10, 2019. e-Pub 2018. PMID: 30301695.
- Balasubramanian A, Metcalfe MJ, Wagenheim G, Xiao L, Papadopoulos J, Navai N, Davis JW, Karam JA, Kamat AM, Wood CG, Dinney CP, Matin SF. Salvage topical therapy for upper tract urothelial carcinoma. World J Urol 36(12):2027-2034, 2018. e-Pub 2018. PMID: 29804202.
- Cumberbatch MGK, Jubber I, Black PC, Esperto F, Figueroa JD, Kamat AM, Kiemeney L, Lotan Y, Pang K, Silverman DT, Znaor A, Catto JWF. Epidemiology of Bladder Cancer: A Systematic Review and Contemporary Update of Risk Factors in 2018. Eur Urol 74(6):784-795, 2018. e-Pub 2018. PMID: 30268659.
- Ray-Zack MD, Shan Y, Mehta HB, Yu X, Kamat AM, Williams SB. Hospital length of stay following radical cystectomy for muscle-invasive bladder cancer: Development and validation of a population-based prediction model. Urol Oncol, 2018. e-Pub 2018. PMID: 30446462.
- Klaassen Z, Kamat AM, Kassouf W, Gontero P, Villavicencio H, Bellmunt J, van Rhijn BWG, Hartmann A, Catto JWF, Kulkarni GS. Treatment Strategy for Newly Diagnosed T1 High-grade Bladder Urothelial Carcinoma: New Insights and Updated Recommendations. Eur Urol 74(5):597-608, 2018. e-Pub 2018. PMID: 30017405.
- Williams SB, Shan Y, Jazzar U, Mehta HB, Baillargeon JG, Huo J, Senagore AJ, Orihuela E, Tyler DS, Swanson TA, Kamat AM. Comparing Survival Outcomes and Costs Associated With Radical Cystectomy and Trimodal Therapy for Older Adults With Muscle-Invasive Bladder Cancer. JAMA Surg 153(10):881-889, 2018. e-Pub 2018. PMID: 29955780.
- Tabayoyong W, Kamat AM. Current Use and Promise of Urinary Markers for Urothelial Cancer. Curr Urol Rep 19(12):96, 2018. e-Pub 2018. PMID: 30328534.
- Hermans TJN, Voskuilen CS, van der Heijden MS, Schmitz-Dräger BJ, Kassouf W, Seiler R, Kamat AM, Grivas P, Kiltie AE, Black PC, van Rhijn BWG. Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. Urol Oncol 36(9):413-422, 2018. e-Pub 2017. PMID: 29128420.
- Kukreja JB, Porten S, Golla V, Ho PL, Noguera-Gonzalez G, Navai N, Kamat AM, Dinney CPN, Shah JB. Absence of Tumor on Repeat Transurethral Resection of Bladder Tumor Does Not Predict Final Pathologic T0 Stage in Bladder Cancer Treated with Radical Cystectomy. Eur Urol Focus 4(5):720-724, 2018. e-Pub 2017. PMID: 28753837.
- Zuiverloon TCM, van Kessel KEM, Bivalacqua TJ, Boormans JL, Ecke TH, Grivas PD, Kiltie AE, Liedberg F, Necchi A, van Rhijn BW, Roghmann F, Sanchez-Carbayo M, Schmitz-Dräger BJ, Wezel F, Kamat AM. Recommendations for follow-up of muscle-invasive bladder cancer patients: A consensus by the international bladder cancer network. Urol Oncol 36(9):423-431, 2018. e-Pub 2018. PMID: 29496372.
- Jazzar U, Yong S, Klaassen Z, Huo J, Hughes BD, Esparza E, Mehta HB, Kim SP, Tyler DS, Freedland SJ, Kamat AM, Wolf DV, Williams SB. Impact of psychiatric illness on decreased survival in elderly patients with bladder cancer in the United States. Cancer 124(15):3127-3135, 2018. e-Pub 2018. PMID: 29660813.
- Flannery K, Cao X, He J, Zhong Y, Shah AY, Kamat AM. Survival Rates and Health Care Costs for Patients With Advanced Bladder Cancer Treated and Untreated With Chemotherapy. Clin Genitourin Cancer 16(4):e909-e917, 2018. e-Pub 2018. PMID: 29735397.
- Lotan Y, Black PC, Caba L, Chang SS, Cookson MS, Daneshmand S, Kamat AM, McKiernan JM, Pruthi RS, Ritch CR, Steinberg GD, Svatek RS, Zwarthoff EC. Optimal Trial Design for Studying Urinary Markers in Bladder Cancer: A Collaborative Review. Eur Urol Oncol 1(3):223-230, 2018. e-Pub 2018. PMID: 31102625.
- Hahn NM, Necchi A, Loriot Y, Powles T, Plimack ER, Sonpavde G, Roupret M, Kamat AM. Role of Checkpoint Inhibition in Localized Bladder Cancer. Eur Urol Oncol 1(3):190-198, 2018. e-Pub 2018. PMID: 31102620.
- Kukreja JB, Shi Q, Chang CM, Seif MA, Sterling BM, Chen TY, Creel KM, Kamat AM, Dinney CP, Navai N, Shah JB, Wang XS. Patient-Reported Outcomes Are Associated With Enhanced Recovery Status in Patients With Bladder Cancer Undergoing Radical Cystectomy. Surg Innov 25(3):1553350618764218, 2018. e-Pub 2018. PMID: 29557251.
- Cumberbatch MGK, Foerster B, Catto JWF, Kamat AM, Kassouf W, Jubber I, Shariat SF, Sylvester RJ, Gontero P. Repeat Transurethral Resection in Non-muscle-invasive Bladder Cancer: A Systematic Review. Eur Urol 73(6):925-933, 2018. e-Pub 2018. PMID: 29523366.
- Daneshmand S, Patel S, Lotan Y, Pohar K, Trabulsi E, Woods M, Downs T, Huang W, Jones J, O'Donnell M, Bivalacqua T, DeCastro J, Steinberg G, Kamat A, Resnick M, Konety B, Schoenberg M, Jones JS, Flexible Blue Light Study Group Collaborators. Efficacy and Safety of Blue Light Flexible Cystoscopy With Hexaminolevulinate (HAL) in the Surveillance of Bladder Cancer: A Phase III, Comparative, Multi-Center Study. J Urol 199(5):1158-1165, 2018. e-Pub 2017. PMID: 29203268.
- Abufaraj M, Dalbagni G, Daneshmand S, Horenblas S, Kamat AM, Kanzaki R, Zlotta AR, Shariat SF. The Role of Surgery in Metastatic Bladder Cancer: A Systematic Review. Eur Urol 73(4):543-557, 2018. e-Pub 2017. PMID: 29122377.
- Li R, Spiess PE, Kamat AM. Treatment Options for Patients with Recurrent Tumors After BCG Therapy: Are We Ignoring the Obvious?. Eur Urol, 2018. e-Pub 2018. PMID: 29685644.
- Li R, Metcalfe MJ, Ferguson JE, Mokkapati S, Nogueras González GM, Dinney CP, Navai N, McConkey DJ, Sahai SK, Kamat AM. Effects of thiazolidinedione in patients with active bladder cancer. BJU Int 121(2):244-251, 2018. e-Pub 2017. PMID: 28872778.
- Guo CC, Al-Ahmadie HA, Flaig TW, Kamat AM. Contribution of bladder cancer pathology assessment in planning clinical trials. Urol Oncol, 2018. e-Pub 2018. PMID: 29395955.
- Lee EK, Kamat AM. Should we care more about SPARE?. BJU Int 120(5):605-606, 2017. PMID: 29035018.
- Jinesh GG, Kamat AM. The Blebbishield Emergency Program Overrides Chromosomal Instability and Phagocytosis Checkpoints in Cancer Stem Cells. Cancer Res 77(22):6144-6156, 2017. e-Pub 2017. PMID: 28855211.
- Kamat AM, Bellmunt J, Galsky MD, Konety BR, Lamm DL, Langham D, Lee CT, Milowsky MI, O'Donnell MA, O'Donnell PH, Petrylak DP, Sharma P, Skinner EC, Sonpavde G, Taylor JA, Abraham P, Rosenberg JE. Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of bladder carcinoma. J Immunother Cancer 5(1):68, 2017. e-Pub 2017. PMID: 28807024.
- Huo J, Chu Y, Chamie K, Smaldone MC, Boorjian SA, Baillargeon JG, Kuo YF, Kerr P, O'Malley P, Orihuela E, Tyler DS, Freedland SJ, Giordano SH, Vikram R, Kamat AM, Williams SB. Increased Utilization of Positron Emission Tomography/Computed Tomography (PET/CT) Imaging and Its Economic Impact for Patients Diagnosed with Bladder Cancer. Clin Genitourin Cancer, 2017. PMID: 28826932.
- Kamat AM, Lerner S, Black P, Bellmunt J, Dinney C, Hahn NM, O'Donnell M, Quale DZ. Once BCG Unresponsive, Always BCG Unresponsive: An Open Letter to the FDA to Enhance Recruitment into Clinical Trials in Bladder Cancer. Bladder Cancer 3(3):145-146, 2017. e-Pub 2017. PMID: 28824940.
- Jinesh GG, Kamat AM. RalBP1 and p19-VHL play an oncogenic role, and p30-VHL plays a tumor suppressor role during the blebbishield emergency program. Cell Death Discov 3:17023, 2017. e-Pub 2017. PMID: 28580172.
- Mbeutcha A, Rouprêt M, Kamat AM, Karakiewicz PI, Lawrentschuk N, Novara G, Raman JD, Seitz C, Xylinas E, Shariat SF. Prognostic factors and predictive tools for upper tract urothelial carcinoma: a systematic review. World J Urol 35(3):337-353, 2017. e-Pub 2016. PMID: 27101100.
- Qu K, Gu J, Ye Y, Williams SB, Dinney CP, Wu X, Kamat AM. High baseline levels of interleukin-8 in leukocytes and urine predict tumor recurrence in non-muscle invasive bladder cancer patients receiving bacillus Calmette-Guerin therapy: A long-term survival analysis. Oncoimmunology 6(2):e1265719, 2017. e-Pub 2017. PMID: 28344874.
- Kamat AM, Hahn NM, Efstathiou JA, Lerner SP, Malmström PU, Choi W, Guo CC, Lotan Y, Kassouf W. Bladder cancer. Lancet 388(10061):2796-2810, 2016. e-Pub 2016. PMID: 27345655.
- Mmeje CO, Guo CC, Shah JB, Navai N, Grossman HB, Dinney CP, Kamat AM. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design. Eur Urol 70(5):778-785, 2016. e-Pub 2016. PMID: 26922408.
- Parker WP, Ho PL, Boorjian SA, Melquist JJ, Thapa P, Holzbeierlein JM, Frank I, Kamat AM, Lee EK. The importance of clinical stage among patients with a complete pathologic response at radical cystectomy after neoadjuvant chemotherapy. World J Urol 34(11):1561-1566, 2016. e-Pub 2016. PMID: 26943643.
- Navai N, Benedict WF, Zhang G, Abraham A, Ainslie N, Shah JB, Grossman HB, Kamat AM, Dinney CP. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette-Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer. Ann Surg Oncol 23(12):4110-4114, 2016. e-Pub 2016. PMID: 27387678.
- Guo CC, Dadhania V, Zhang L, Majewski T, Bondaruk J, Sykulski M, Wronowska W, Gambin A, Wang Y, Zhang S, Fuentes-Mattei E, Kamat AM, Dinney C, Siefker-Radtke A, Choi W, Baggerly KA, McConkey D, Weinstein JN, Czerniak B. Gene Expression Profile of the Clinically Aggressive Micropapillary Variant of Bladder Cancer. Eur Urol 70(4):611-620, 2016. e-Pub 2016. PMID: 26988609.
- Kassouf W, Traboulsi SL, Schmitz-Dräger B, Palou J, Witjes JA, van Rhijn BW, Grossman HB, Kiemeney LA, Goebell PJ, Kamat AM. Follow-up in non-muscle-invasive bladder cancer-International Bladder Cancer Network recommendations. Urol Oncol 34(10):460-8, 2016. e-Pub 2016. PMID: 27368880.
- Schmitz-Dräger BJ, Kuckuck EC, Zuiverloon TC, Zwarthoff EC, Saltzman A, Srivastava A, Hudson MA, Seiler R, Todenhöfer T, Vlahou A, Grossman HB, Schoenberg MP, Sanchez-Carbayo M, Brünn LA, van Rhijn BW, Goebell PJ, Kamat AM, Roupret M, Shariat SF, Kiemeney LA. Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. Urol Oncol 34(10):437-51, 2016. e-Pub 2016. PMID: 27641313.
- Takeuchi H, Taoka R, Mmeje CO, Jinesh GG, Safe S, Kamat AM. CDODA-Me decreases specificity protein transcription factors and induces apoptosis in bladder cancer cells through induction of reactive oxygen species. Urol Oncol 34(8):337.e11-8, 2016. e-Pub 2016. PMID: 27038699.
- Oshiro H, Czerniak BA, Sakamaki K, Tsuta K, Bondaruk J, Keyhani A, Dinney CP, Nagai T, Kamat AM. Comparison between whole mount tissue preparations and virtual tissue microarray samples for measuring Ki-67 and apoptosis indices in human bladder cancer: A cross-sectional study. Medicine (Baltimore) 95(31):e4500, 2016. PMID: 27495099.
- Kamat AM, Sylvester RJ, Böhle A, Palou J, Lamm DL, Brausi M, Soloway M, Persad R, Buckley R, Colombel M, Witjes JA. Definitions, End Points, and Clinical Trial Designs for Non-Muscle-Invasive Bladder Cancer: Recommendations From the International Bladder Cancer Group. J Clin Oncol 34(16):1935-44, 2016. e-Pub 2016. PMID: 26811532.
- Kamat AM, Willis DL, Dickstein RJ, Anderson R, Nogueras-González G, Katz RL, Wu X, Barton Grossman H, Dinney CP. A novel FISH-based definition of BCG failure to enhance recruitment into clinical trials of intravesical therapies. BJU Int 117(5):754-60, 2016. e-Pub 2015. PMID: 26032953.
- McConkey DJ, Choi W, Shen Y, Lee IL, Porten S, Matin SF, Kamat AM, Corn P, Millikan RE, Dinney C, Czerniak B, Siefker-Radtke AO. A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy: A Phase 2 Trial of Dose-dense Methotrexate, Vinblastine, Doxorubicin, and Cisplatin with Bevacizumab in Urothelial Cancer. Eur Urol 69(5):855-62, 2016. e-Pub 2015. PMID: 26343003.
- Donovan FX, Kimble DC, Kim Y, Lach FP, Harper U, Kamat AM, Jones M, Sanborn EM, Tryon R, Wagner JE, MacMillan ML, Ostrander EA, Auerbach AD, Smogorzewska A, Chandrasekharappa SC. Paternal or Maternal Uniparental Disomy of Chromosome 16 Resulting in Homozygosity of a Mutant Allele Causes Fanconi Anemia. Hum Mutat 37(5):465-8, 2016. e-Pub 2016. PMID: 26841305.
- Jinesh GG, Kamat AM. Blebbishield emergency program: an apoptotic route to cellular transformation. Cell Death Differ 23(5):757-8, 2016. e-Pub 2016. PMID: 26967969.
- Jinesh GG, Taoka R, Zhang Q, Gorantla S, Kamat AM. Novel PKC-ζ to p47(phox) interaction is necessary for transformation from blebbishields. Sci Rep 6:23965, 2016. e-Pub 2016. PMID: 27040869.
- Lerner SP, Bajorin DF, Dinney CP, Efstathiou JA, Groshen S, Hahn NM, Hansel D, Kwiatkowski D, O'Donnell M, Rosenberg J, Svatek R, Abrams JS, Al-Ahmadie H, Apolo AB, Bellmunt J, Callahan M, Cha EK, Drake C, Jarow J, Kamat A, Kim W, Knowles M, Mann B, Marchionni L, McConkey D, McShane L, Ramirez N, Sharabi A, Sharpe AH, Solit D, Tangen CM, Amiri AT, Van Allen E, West PJ, Witjes JA, Quale DZ. Summary and Recommendations from the National Cancer Institute's Clinical Trials Planning Meeting on Novel Therapeutics for Non-Muscle Invasive Bladder Cancer. Bladder Cancer 2(2):165-202, 2016. e-Pub 2016. PMID: 27376138.
- Kamat AM, Cookson M, Witjes JA, Stenzl A, Grossman HB. The Impact of Blue Light Cystoscopy with Hexaminolevulinate (HAL) on Progression of Bladder Cancer - A New Analysis. Bladder Cancer 2(2):273-278, 2016. e-Pub 2016. PMID: 27376146.
- Figueroa JD, Middlebrooks CD, Banday AR, Ye Y, Garcia-Closas M, Chatterjee N, Koutros S, Kiemeney LA, Rafnar T, Bishop T, Furberg H, Matullo G, Golka K, Gago-Dominguez M, Taylor JA, Fletcher T, Siddiq A, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue MP, Jacobs EJ, Albanes D, Wang Z, Chung CC, Vermeulen SH, Aben KK, Galesloot TE, Thorleifsson G, Sulem P, Stefansson K, Kiltie AE, Harland M, Teo M, Offit K, Vijai J, Bajorin D, Kopp R, Fiorito G, Guarrera S, Sacerdote C, Selinski S, Hengstler JG, Gerullis H, Ovsiannikov D, Blaszkewicz M, Castelao JE, Calaza M, Martinez ME, Cordeiro P, Xu Z, Panduri V, Kumar R, Gurzau E, Koppova K, Bueno-De-Mesquita HB, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis RC, Tjønneland A, Brennan P, Chang-Claude J, Riboli E, Conti D, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Jeppson RP, Cancel-Tassin G, Roupret M, Comperat E, Turman C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Zhang L, Gong Y, Pu X, Hutchinson A, Burdett L, Wheeler WA, Karagas MR, Johnson A, Schned A, Monawar Hosain GM, Schwenn M, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Andriole G, Grubb R, Black A, Diver WR, Gapstur SM, Weinstein S, Virtamo J, Haiman CA, Landi MT, Caporaso NE, Fraumeni JF, Vineis P, Wu X, Chanock SJ, Silverman DT, Prokunina-Olsson L, Rothman N. Identification of a novel susceptibility locus at 13q34 and refinement of the 20p12.2 region as a multi-signal locus associated with bladder cancer risk in individuals of European ancestry. Hum Mol Genet 25(6):1203-14, 2016. e-Pub 2016. PMID: 26732427.
- Kamat AM, Briggman J, Urbauer DL, Svatek R, Nogueras González GM, Anderson R, Grossman HB, Prat F, Dinney CP. Cytokine Panel for Response to Intravesical Therapy (CyPRIT): Nomogram of Changes in Urinary Cytokine Levels Predicts Patient Response to Bacillus Calmette-Guérin. Eur Urol 69(2):197-200, 2016. e-Pub 2015. PMID: 26119560.
- Ho PL, Willis DL, Patil J, Xiao L, Williams SB, Melquist JJ, Tart K, Parikh S, Shah JB, Delacroix SE, Navai N, Siefker-Radtke A, Dinney CP, Pisters LL, Kamat AM. Outcome of patients with clinically node-positive bladder cancer undergoing consolidative surgery after preoperative chemotherapy: The M.D. Anderson Cancer Center Experience. Urol Oncol 34(2):59.e1-8, 2016. e-Pub 2015. PMID: 26421586.
- Jinesh GG, Laing NM, Kamat AM. Smac mimetic with TNF-α targets Pim-1 isoforms and reactive oxygen species production to abrogate transformation from blebbishields. Biochem J 473(1):99-107, 2016. e-Pub 2015. PMID: 26508734.
- Pierzynski JA, Hildebrandt MA, Kamat AM, Lin J, Ye Y, Dinney CP, Wu X. Genetic Variants in the Wnt/β-Catenin Signaling Pathway as Indicators of Bladder Cancer Risk. J Urol 194(6):1771-6, 2015. e-Pub 2015. PMID: 26173102.
- Dhillon J, Liang Y, Kamat AM, Siefker-Radtke A, Dinney CP, Czerniak B, Guo CC. Urachal carcinoma: a pathologic and clinical study of 46 cases. Hum Pathol 46(12):1808-14, 2015. e-Pub 2015. PMID: 26364859.
- Takeuchi H, Mmeje CO, Jinesh GG, Taoka R, Kamat AM. Sequential gemcitabine and tamoxifen treatment enhances apoptosis and blocks transformation in bladder cancer cells. Oncol Rep 34(5):2738-44, 2015. e-Pub 2015. PMID: 26323344.
- Williams SB, Ye Y, Huang M, Chang DW, Kamat AM, Pu X, Dinney CP, Wu X. Mitochondrial DNA Content as Risk Factor for Bladder Cancer and its Association with Mitochondrial DNA Polymorphisms. Cancer Prev Res (Phila) 8(7):607-13, 2015. e-Pub 2015. PMID: 25896234.
- Parker WP, Ho PL, Melquist JJ, Scott K, Holzbeierlein JM, Lopez-Corona E, Kamat AM, Lee EK. The Effect of Concomitant Carcinoma In Situ on Neoadjuvant Chemotherapy for Urothelial Cell Carcinoma of the Bladder: Inferior Pathological Outcomes but No Effect on Survival. J Urol 193(5):1494-9, 2015. e-Pub 2014. PMID: 25451834.
- Breen V, Kasabov N, Kamat AM, Jacobson E, Suttie JM, O'Sullivan PJ, Kavalieris L, Darling DG. A holistic comparative analysis of diagnostic tests for urothelial carcinoma: a study of Cxbladder Detect, UroVysion® FISH, NMP22® and cytology based on imputation of multiple datasets. BMC Med Res Methodol 15:45, 2015. e-Pub 2015. PMID: 25962444.
- Willis DL, Fernandez MI, Dickstein RJ, Parikh S, Shah JB, Pisters LL, Guo CC, Henderson S, Czerniak BA, Grossman HB, Dinney CP, Kamat AM. Clinical Outcomes in cT1 Micropapillary Bladder Cancer. J Urol 193(4):1129-34, 2015. e-Pub 2014. PMID: 25254936.
- Morales A, Herr H, Steinberg G, Given R, Cohen Z, Amrhein J, Kamat AM. Efficacy and Safety of MCNA in Patients with Non-Muscle Invasive Bladder Cancer at High-Risk of Recurrence and Progression who Have Failed Treatment with Bacillus Calmette-Guérin. J Urol 193(4):1135-43, 2015. e-Pub 2014. PMID: 25286009.
- Kamat AM, Flaig TW, Grossman HB, Konety B, Lamm D, O'Donnell MA, Uchio E, Efstathiou JA, Taylor JA. Expert consensus document: Consensus statement on best practice management regarding the use of intravesical immunotherapy with BCG for bladder cancer. Nat Rev Urol 12(4):225-35, 2015. e-Pub 2015. PMID: 25800393.
- Taoka R, Williams SB, Ho PL, Kamat AM. In-vitro cytocidal effect of water on bladder cancer cells: The potential role for intraperitoneal lavage during radical cystectomy. Can Urol Assoc J 9(3-4):E109-13, 2015. PMID: 25844095.
- Ho PL, Williams SB, Kamat AM. Immune therapies in non-muscle invasive bladder cancer. Curr Treat Options Oncol 16(2):315, 2015. PMID: 25757877.
- Wang Z, Zhu B, Zhang M, Parikh H, Jia J, Chung CC, Sampson JN, Hoskins JW, Hutchinson A, Burdette L, Ibrahim A, Hautman C, Raj PS, Abnet CC, Adjei AA, Ahlbom A, Albanes D, Allen NE, Ambrosone CB, Aldrich M, Amiano P, Amos C, Andersson U, Andriole G, Andrulis IL, Arici C, Arslan AA, Austin MA, Baris D, Barkauskas DA, Bassig BA, Beane Freeman LE, Berg CD, Berndt SI, Bertazzi PA, Biritwum RB, Black A, Blot W, Boeing H, Boffetta P, Bolton K, Boutron-Ruault MC, Bracci PM, Brennan P, Brinton LA, Brotzman M, Bueno-de-Mesquita HB, Buring JE, Butler MA, Cai Q, Cancel-Tassin G, Canzian F, Cao G, Caporaso NE, Carrato A, Carreon T, Carta A, Chang GC, Chang IS, Chang-Claude J, Che X, Chen CJ, Chen CY, Chen CH, Chen C, Chen KY, Chen YM, Chokkalingam AP, Chu LW, Clavel-Chapelon F, Colditz GA, Colt JS, Conti D, Cook MB, Cortessis VK, Crawford ED, Cussenot O, Davis FG, De Vivo I, Deng X, Ding T, Dinney CP, Di Stefano AL, Diver WR, Duell EJ, Elena JW, Fan JH, Feigelson HS, Feychting M, Figueroa JD, Flanagan AM, Fraumeni JF, Freedman ND, Fridley BL, Fuchs CS, Gago-Dominguez M, Gallinger S, Gao YT, Gapstur SM, Garcia-Closas M, Garcia-Closas R, Gastier-Foster JM, Gaziano JM, Gerhard DS, Giffen CA, Giles GG, Gillanders EM, Giovannucci EL, Goggins M, Gokgoz N, Goldstein AM, Gonzalez C, Gorlick R, Greene MH, Gross M, Grossman HB, Grubb R, Gu J, Guan P, Haiman CA, Hallmans G, Hankinson SE, Harris CC, Hartge P, Hattinger C, Hayes RB, He Q, Helman L, Henderson BE, Henriksson R, Hoffman-Bolton J, Hohensee C, Holly EA, Hong YC, Hoover RN, Hosgood HD, Hsiao CF, Hsing AW, Hsiung CA, Hu N, Hu W, Hu Z, Huang MS, Hunter DJ, Inskip PD, Ito H, Jacobs EJ, Jacobs KB, Jenab M, Ji BT, Johansen C, Johansson M, Johnson A,Kaaks R, Kamat AM,Kamineni A,Karagas M, Khanna C, Khaw KT, Kim C, Kim IS,Kim JH, Kim YH, Kim YC, Kim YT, Kang CH, Jung YJ, Kitahara CM, Klein AP, Klein R, Kogevinas M, Koh WP, Kohno T, Kolonel LN, Kooperberg C, Kratz CP, Krogh V, Kunitoh H, Kurtz RC, Kurucu N, Lan Q, Lathrop M, Lau CC,. Imputation and subset-based association analysis across different cancer types identifies multiple independent risk loci in the TERT-CLPTM1L region on chromosome 5p15.33. Hum Mol Genet 23(24):6616-33, 2014. e-Pub 2014. PMID: 25027329.
- Li W, Liang Y, Deavers MT, Kamat AM, Matin SF, Dinney CP, Czerniak B, Guo CC. Uroplakin II is a more sensitive immunohistochemical marker than uroplakin III in urothelial carcinoma and its variants. Am J Clin Pathol 142(6):864-71, 2014. PMID: 25389341.
- Svatek RS, Clinton TN, Wilson CA, Kamat AM, Grossman HB, Dinney CP, Shah JB. Intravesical Tumor Involvement of the Trigone Is Associated With Nodal Metastasis in Patients Undergoing Radical Cystectomy. Urology 84(5):1147-51, 2014. e-Pub 2014. PMID: 25174656.
- Schmitz-Dräger BJ, Todenhöfer T, van Rhijn B, Pesch B, Hudson MA, Chandra A, Ingersoll MA, Kassouf W, Palou J, Taylor J, Vlahou A, Behrens T, Critelli R, Grossman HB, Sanchez-Carbayo M, Kamat AM. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non-muscle invasive bladder cancer. Urol Oncol 32(7):1061-8, 2014. e-Pub 2014. PMID: 24411790.
- Goebell PJ, Kamat AM, Sylvester RJ, Black P, Droller M, Godoy G, Hudson MA, Junker K, Kassouf W, Knowles MA, Schulz WA, Seiler R, Schmitz-Dräger BJ. Assessing the quality of studies on the diagnostic accuracy of tumor markers. Urol Oncol 32(7):1051-60, 2014. e-Pub 2014. PMID: 25159014.
- Kamat AM, Lamm DL. Predicting response to bacillus calmette-guérin: time to look beyond the ages. Eur Urol 66(4):702-3, 2014. e-Pub 2014. PMID: 24968969.
- Daneshmand S, Schuckman AK, Bochner BH, Cookson MS, Downs TM, Gomella LG, Grossman HB, Kamat AM, Konety BR, Lee CT, Pohar KS, Pruthi RS, Resnick MJ, Smith ND, Witjes JA, Schoenberg MP, Steinberg GD. Hexaminolevulinate blue-light cystoscopy in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on appropriate use in the USA. Nat Rev Urol 11(10):589-96, 2014. e-Pub 2014. PMID: 25245244.
- Kamat AM, Vlahou A, Taylor JA, Hudson ML, Pesch B, Ingersoll MA, Todenhöfer T, van Rhijn B, Kassouf W, Barton Grossman H, Behrens T, Chandra A, Goebell PJ, Palou J, Sanchez-Carbayo M, Schmitz-Dräger BJ. Considerations on the use of urine markers in the management of patients with high-grade non-muscle-invasive bladder cancer. Urol Oncol 32(7):1069-77, 2014. e-Pub 2014. PMID: 25306288.
- Lee CT, Chang SS, Kamat AM, Amiel G, Beard TL, Fergany A, Karnes RJ, Kurz A, Menon V, Sexton WJ, Slaton JW, Svatek RS, Wilson SS, Techner L, Bihrle R, Steinberg GD, Koch M. Alvimopan Accelerates Gastrointestinal Recovery After Radical Cystectomy: A Multicenter Randomized Placebo-Controlled Trial. Eur Urol 66(2):265-72, 2014. e-Pub 2014. PMID: 24630419.
- Kamat AM, Witjes JA, Brausi M, Soloway M, Lamm D, Persad R, Buckley R, Böhle A, Colombel M, Palou J. Defining and Treating the Spectrum of Intermediate-Risk NMIBC. J Urol 192(2):305-15, 2014. e-Pub 2014. PMID: 24681333.
- Willis DL, Flaig TW, Hansel DE, Milowsky MI, Grubb RL, Al-Ahmadie HA, Plimack ER, Koppie TM, McConkey DJ, Dinney CP, Hoffman VA, Droller MJ, Messing E, Kamat AM. Micropapillary bladder cancer: Current treatment patterns and review of the literature. Urol Oncol 32(6):826-32, 2014. e-Pub 2014. PMID: 24931270.
- Liang Y, Heitzman J, Kamat AM, Dinney CP, Czerniak B, Guo CC. Differential expression of GATA-3 in urothelial carcinoma variants. Hum Pathol 45(7):1466-72, 2014. e-Pub 2014. PMID: 24745616.
- Kauf TL, Svatek RS, Amiel G, Beard TL, Chang SS, Fergany A, Karnes RJ, Koch M, O'Hara J, Lee CT, Sexton WJ, Slaton JW, Steinberg GD, Wilson SS, Techner L, Martin C, Moreno J, Kamat AM. Alvimopan, a Peripherally Acting Mu-Opioid Receptor Antagonist, Is Associated with Reduced Costs After Radical Cystectomy-Economic Analysis of a Phase 4 Randomized, Controlled Trial. J Urol 191(6):1721-7, 2014. e-Pub 2013. PMID: 24342144.
- Porten S, Siefker-Radtke AO, Xiao L, Margulis V, Kamat AM, Wood CG, Jonasch E, Dinney CP, Matin SF. Neoadjuvant chemotherapy improves survival of patients with upper tract urothelial carcinoma. Cancer 120(12):1794-9, 2014. e-Pub 2014. PMID: 24633966.
- Pisters AL, Kamat AM, Wei W, Leibovici D, Liu J, Grossman HB, Butler CE. Anterior fascial fixation does not reduce the parastomal hernia rate after radical cystectomy and ileal conduit. Urology 83(6):1427-32, 2014. e-Pub 2014. PMID: 24768021.
- Hoang AN, Agarwal PK, Walton-Diaz A, Wood CG, Metwalli AR, Kassouf W, Brown GA, Black PC, Urbauer DL, Grossman HB, Dinney CP, Kamat AM. Clinical Significance of Ureteral "Skip Lesions" at the Time of Radical Cystectomy: the MD Anderson Experience and Review of Literature. BJU Int 113(5b):E28-33, 2014. e-Pub 2013. PMID: 24053608.
- Messer JC, Shariat SF, Dinney CP, Novara G, Fradet Y, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Lotan Y, Skinner EC, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Wei C, Lerner SP, Curiel TJ, Kamat AM, Svatek RS. Female gender is associated with a worse survival after radical cystectomy for urothelial carcinoma of the bladder: a competing risk analysis. Urology 83(4):863-8, 2014. e-Pub 2014. PMID: 24485993.
- Gray PJ, Lin CC, Jemal A, Shipley WU, Fedewa SA, Kibel AS, Rosenberg JE, Kamat AM, Virgo KS, Blute ML, Zietman AL, Efstathiou JA. Clinical-pathologic stage discrepancy in bladder cancer patients treated with radical cystectomy: results from the national cancer data base. Int J Radiat Oncol Biol Phys 88(5):1048-56, 2014. PMID: 24661658.
- Onaiwu CO, Ramirez PT, Kamat AM, Pagliaro LC, Euscher EE, Schmeler KM. Invasive extramammary Paget's disease of the bladder diagnosed 18 years after noninvasive extramammary Paget's disease of the vulva. Gynecol Oncol Case Rep 8:27-9, 2014. e-Pub 2014. PMID: 24809008.
- Figueroa JD, Ye Y, Siddiq A, Garcia-Closas M, Chatterjee N, Prokunina-Olsson L, Cortessis VK, Kooperberg C, Cussenot O, Benhamou S, Prescott J, Porru S, Dinney CP, Malats N, Baris D, Purdue M, Jacobs EJ, Albanes D, Wang Z, Deng X, Chung CC, Tang W, Bas Bueno-de-Mesquita H, Trichopoulos D, Ljungberg B, Clavel-Chapelon F, Weiderpass E, Krogh V, Dorronsoro M, Travis R, Tjønneland A, Brenan P, Chang-Claude J, Riboli E, Conti D, Gago-Dominguez M, Stern MC, Pike MC, Van Den Berg D, Yuan JM, Hohensee C, Rodabough R, Cancel-Tassin G, Roupret M, Comperat E, Chen C, De Vivo I, Giovannucci E, Hunter DJ, Kraft P, Lindstrom S, Carta A, Pavanello S, Arici C, Mastrangelo G, Kamat AM, Lerner SP, Barton Grossman H, Lin J, Gu J, Pu X, Hutchinson A, Burdette L, Wheeler W, Kogevinas M, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Schwenn M, Karagas MR, Johnson A, Schned A, Armenti KR, Hosain GM, Andriole G, Grubb R, Black A, Ryan Diver W, Gapstur SM, Weinstein SJ, Virtamo J, Haiman CA, Landi MT, Caporaso N, Fraumeni JF, Vineis P, Wu X, Silverman DT, Chanock S, Rothman N. Genome-wide association study identifies multiple loci associated with bladder cancer risk. Hum Mol Genet 23(5):1387-98, 2014. e-Pub 2013. PMID: 24163127.
- Culp SH, Dickstein RJ, Grossman HB, Pretzsch SM, Porten S, Daneshmand S, Cai J, Groshen S, Siefker-Radtke A, Millikan RE, Czerniak B, Navai N, Wszolek MF, Kamat AM, Dinney CP. Refining Patient Selection for Neoadjuvant Chemotherapy Prior to Radical Cystectomy. J Urol 191(1), 2014. PMID: 23911605.
- Lamm D, Persad R, Brausi M, Buckley R, Witjes JA, Palou J, Böhle A, Kamat AM, Colombel M, Soloway M. Defining Progression in Non-Muscle Invasive Bladder Cancer (NMIBC): It's Time for a New, Standard Definition. J Urol 191(1):20-7, 2014. e-Pub 2013. PMID: 23973937.
- Jinesh G G, Lee EK, Tran J, Kamat AM. Lenalidomide augments the efficacy of bacillus Calmette-Guerin (BCG) immunotherapy in vivo. Urol Oncol 31(8), 2013. PMID: 22717623.
- Fernández MI, Gong Y, Ye Y, Lin J, Chang DW, Kamat AM, Wu X. Gamma-H2AX Level in Peripheral Blood Lymphocytes as a Risk Predictor for Bladder Cancer. Carcinogenesis 34(11):2543-7, 2013. e-Pub 2013. PMID: 23946494.
- Abel EJ, Fisher MB, Matin SF, Kamat AM, Dinney CP, Grossman HB. Delayed ureterectomy after incomplete nephroureterectomy for upper tract urothelial carcinoma: pathologic findings and outcomes. Int Braz J Urol 39(6):817-22, 2013. PMID: 24456786.
- Dayyani F, Pettaway CA, Kamat AM, Munsell MF, Sircar K, Pagliaro LC. Retrospective analysis of survival outcomes and the role of cisplatin-based chemotherapy in patients with urethral carcinomas referred to medical oncologists(☆). Urol Oncol 31(7):1171-7, 2013. e-Pub 2012. PMID: 22534087.
- Witjes JA, Palou J, Soloway M, Lamm D, Kamat AM, Brausi M, Persad R, Buckley R, Colombel M, Böhle A. Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guérin (BCG): results of an international individual patient data survey (IPDS). BJU Int 112(6):742-50, 2013. e-Pub 2013. PMID: 23452187.
- Dinney CP, Fisher MB, Navai N, O'Donnell MA, Cutler D, Abraham A, Young S, Hutchins B, Caceres M, Kishnani N, Sode G, Cullen C, Zhang G, Grossman HB, Kamat AM, Gonzales M, Kincaid M, Ainslie N, Maneval DC, Wszolek MF, Benedict WF. Phase I Trial of Intravesical Recombinant Adenovirus-Mediated Interferon-α2b Formulated in Syn3 for BCG failures in Non-Muscle-Invasive Bladder Cancer. J Urol 190(3):850-6, 2013. e-Pub 2013. PMID: 23507396.
- Lee EK, Jinesh G G, Laing NM, Choi W, McConkey DJ, Kamat AM. A Smac mimetic augments the response of urothelial cancer cells to gemcitabine and cisplatin. Cancer Biol Ther 14(9):812-22, 2013. e-Pub 2013. PMID: 23792592.
- Lotan Y, Amiel G, Boorjian SA, Clark PE, Droller M, Gingrich JR, Guzzo TJ, Inman BA, Kamat AM, Karsh L, Nielsen ME, Smith ND, Shariat SF, Svatek RS, Taylor JM, Bladder Cancer Think Tank, Bladder Cancer Advocacy Network. Comprehensive handbook for developing a bladder cancer cystectomy database. Urol Oncol 31(6):812-26, 2013. e-Pub 2011. PMID: 22056403.
- Wang J, Wu X, Kamat AM, Barton Grossman H, Dinney CP, Lin J. Fluid intake, genetic variants of UDP-glucuronosyltransferases, and bladder cancer risk. Br J Cancer 108(11):2372-80, 2013. e-Pub 2013. PMID: 23632476.
- Kassouf W, Svatek RS, Shariat SF, Novara G, Lerner SP, Fradet Y, Bastian PJ, Aprikian A, Karakiewicz PI, Fritsche HM, Dinney CP, Tilki D, Kamat AM, Izawa JI, Ficarra V, Lotan Y, Sagalowsky AI, Schoenberg MP, Skinner EC. Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol 31(4):480-6, 2013. e-Pub 2011. PMID: 21478035.
- Lee EK, Ye Y, Kamat AM, Wu X. Genetic variations in regulator of G-protein signaling (RGS) confer risk of bladder cancer. Cancer 119(9):1643-51, 2013. e-Pub 2013. PMID: 23529717.
- Chauhan S, Goodwin JG, Chauhan S, Manyam G, Wang J, Kamat AM, Boyd DD. ZKSCAN3 Is a Master Transcriptional Repressor of Autophagy. Mol Cell 50(1):16-28, 2013. e-Pub 2013. PMID: 23434374.
- Siefker-Radtke AO, Dinney CP, Shen Y, Williams DL, Kamat AM, Grossman HB, Millikan RE. A phase 2 clinical trial of sequential neoadjuvant chemotherapy with ifosfamide, doxorubicin, and gemcitabine followed by cisplatin, gemcitabine, and ifosfamide in locally advanced urothelial cancer: Final results. Cancer 119(3):540-7, 2013. e-Pub 2012. PMID: 22914978.
- Davis JW, Kamat AM. Lymphadenectomy with robotic cystectomy. Curr Urol Rep 14(1):Feb;14(1):59-63, 2013. PMID: 23138180.
- Jinesh GG, Choi W, Shah JB, Lee EK, Willis DL, Kamat AM. Blebbishields, the emergency program for cancer stem cells: sphere formation and tumorigenesis after apoptosis. Cell Death Differ 20(3):382-95, 2013. PMID: 23175184.
- Kamat AM, Hegarty PK, Gee JR, Clark PE, Svatek RS, Hegarty N, Shariat SF, Xylinas E, Schmitz-Dräger BJ, Lotan Y, Jenkins LC, Droller M, van Rhijn BW, Karakiewicz PI, International Consultation on Urologic Disease-European Association of Urology Consultation on Bladder Cancer 2012. ICUD-EAU International Consultation on Bladder Cancer 2012: Screening, Diagnosis, and Molecular Markers. Eur Urol 63(1):4-15, 2013. e-Pub 2012. PMID: 23083902.
- Lynch SP, Shen Y, Kamat AM, Grossman HB, Shah JB, Millikan RE, Dinney CP, Siefker-Radtke A.. Neoadjuvant Chemotherapy in Small Cell Urothelial Cancer Improves Pathologic Downstaging and Long-term Outcomes: Results from a Retrospective Study at the MD Anderson Cancer Center. Eur Urol 64(2):307-13, 2013. PMID: 22564397.
- Wei H, Kamat AM, Aldousari S, Ye Y, Huang M, Dinney CP, Wu X.. Genetic variations in the transformation growth factor Beta pathway as predictors of bladder cancer risk. PLoS One 2(12), 2012. PMID: 23251617.
- Fernández MI, Parikh S, Grossman HB, Katz R, Matin SF, Dinney CP, Kamat AM. The role FISH and cytology in upper urinary tract surveillance after radical cystectomoy for bladder cancer. Urol Oncol 30(6):821-4, 2012. e-Pub 2011. PMID: 21396845.
- Dickstein RJ, Nitti G, Dinney CP, Davies BR, Kamat AM, McConkey DJ. Autophagy limits the cytotoxic effects of the AKT inhibitor AZ7328 in human bladder cancer cells. Cancer Biol Ther 13(13):1325-38, 2012. e-Pub 2012. PMID: 22895070.
- Apolo AB, Grossman HB, Bajorin D, Steinberg G, Kamat AM. Practical use of perioperative chemotherapy for muscle-invasive bladder cancer: Summary of session at the Society of Urologic Oncology annual meeting. Urol Oncol 30(6):772-8, 2012. PMID: 23218068.
- Jinesh G G, Kamat AM. Redirecting neutrophils against bladder cancer cells by BCG and Smac mimetic combination. Oncoimmunology 1(7):1161-1162, 2012. PMID: 23170264.
- Wei H, Kamat AM, Chen M, Ke HL, Chang DW, Yin J, Grossman HB, Dinney CP, Wu X. Association of polymorphisms in oxidative stress genes with clinical outcomes for bladder cancer treated with bacillus calmette-guérin. PLoS One 7(6):e38533, 2012. PMID: 22701660.
- Rink M, Shariat SF, Xylinas E, Fitzgerald JP, Hansen J, Green DA, Kamat AM, Novara G, Daneshmand S, Fradet Y, Tagawa ST, Bastian PG, Kassouf W, Trinh QD, Karakiewicz PI, Fritsche HM, Tilki D, Chun FK, Volkmer BG, Babjuk M, Merseburger AS, Scherr DS, Lotan Y, Svatek R. Does increasing the nodal yield improve outcomes in patients without nodal metastasis at radical cystectomy?. World J. Urol 30(6):807-14, 2012. PMID: 22832587.
- Lee EK, Herr HW, Dickstein RJ, Kassouf W, Munsell MF, Grossman HB, Dinney CP, Kamat AM. Lymph node density for patient counselling about prognosis and for designing clinical trials of adjuvent therapies after radical cystectomy. BJU Int 110(11):590-5, 2012. PMID: 22758775.
- Jinesh G G, Chunduru S, Kamat AM. Smac mimetic enables the anticancer action of BCG-stimulated neutrophils through TNF-α but not through TRAIL and FasL. J Leukoc Biol 92(1):233-44, 2012. PMID: 22517918.
- Sundi D, Svatek RS, Margulis V, Wood CG, Matin SF, Dinney CP, Kamat AM. Upper tract urothelial carcinoma: Impact of time to surgery. Urol Oncol 30(3):266-72, 2012. e-Pub 2010. PMID: 20869888.
- Kamat AM, Dickstein RJ, Messetti F, Anderson R, Pretzsch SM, Gonzalez GN, Katz RL, Khanna A, Zaidi T, Wu X, Grossman HB, Dinney CP. Use of flourescence in situ hybridization to predict response to bacillus calmette-guerin therapy for bladder cancer: results of a prespective trial. J Urol 187(3):862-7, 2012. e-Pub 2012. PMID: 22245325.
- Garcia-Closas M, Ye Y, Rothman N, Figueroa JD, Malats N, Dinney CP, Chatterjee N, Prokunina-Olsson L, Wang Z, Lin J, Real FX, Jacobs KB, Baris D, Thun M, De Vivo I, Albanes D, Purdue MP, Kogevinas M, Kamat AM, Lerner SP, Grossman HB, Gu J, Pu X, Hutchinson A, Fu YP, Burdett L, Yeager M, Tang W, Tardón A, Serra C, Carrato A, García-Closas R, Lloreta J, Johnson A, Schwenn M, Karagas MR, Schned A, Andriole G, Grubb R, Black A, Jacobs EJ, Diver WR, Gapstur SM, Weinstein SJ, Virtamo J, Hunter DJ, Caporaso N, Landi MT, Fraumeni JF, Silverman DT, Chanock SJ, Wu X. A genome-wide association study of bladder cancer identifies a new susceptibility locus within SLC14A1, a urea transporter gene on chromosome 18q12.3. Hum Mol Genet 20(21):4282-9, 2011. e-Pub 2011. PMID: 21824976.
- Kamat AM, Karam JA, Grossman HB, Kader AK, Munsell M, Dinney CP. Prospective trial to identify optimal bladder cancer surveillance protocol: reducing costs while maximizing sensitivity. BJU Int 108(7):1119-23, 2011. e-Pub 2011. PMID: 21426474.
- Rajput MZ, Kamat AM, Clavell-Hernandez J, Siefker-Radtke AO, Grossman HB, Dinney CP, Matin SF. Perioperative outcomes of laparoscopic radical nephroureterectomy and regional lymphadenectomy in patients with upper urinary tract urothelial carcinoma after neoadjuvant chemotherapy. Urology 78(1):61-7, 2011. e-Pub 2011. PMID: 21354598.
- Gu J, Chen M, Shete S, Amos CI, Kamat AM, Ye Y, Lin J, Dinney CP, Wu X. A genome-wide association study identifies a locus on chromosome 14q21 as a predictor of leukocyte telomere length and as a marker of susceptibility for bladder cancer. Cancer Prev Res (Phila) 4(4):514-21, 2011. e-Pub 2011. PMID: 21460395.
- Black PC, Dinney CP, Brown GA, Kassouf W, Siefker-Radtke AO, Munsell MF, Grossman HB, Kamat AM. The role of radical cystectomy in patients with clinical T4b bladder cancer. Urol Oncol 29(2):157-61, 2011. e-Pub 2010. PMID: 20456984.
- Svatek RS, Shariat SF, Novara G, Skinner EC, Fradet Y, Bastian PJ, Kamat AM, Kassouf W, Karakiewicz PI, Fritsche HM, Izawa JI, Tilki D, Ficarra V, Volkmer BG, Isbarn H, Dinney CP. Discrepancy between clinical and pathological stage: external validation of the impact on prognosis in an international radical cystectomy cohort. BJU Int 107(6):898-904, 2011. e-Pub 2011. PMID: 21244604.
- Davis JW, Gaston K, Anderson R, Dinney CP, Grossman HB, Munsell MF, Kamat AM. Robot Assisted Extended Pelvic Lymphadenectomy at Radical Cystectomy: Lymph Node Yield Compared with Second Look Open Dissection. J Urol 185(1):79-83, 2011. e-Pub 2010. PMID: 21074799.
- Momoh AO, Kamat AM, Butler CE. Reconstruction of the pelvic floor with human acellular dermal matrix and omental flap following anterior pelvic exenteration. J Plast Reconstr Aesthet Surg 63(12):2185-7, 2010. e-Pub 2010. PMID: 20399719.
- Svatek RS, Fisher MB, Williams MB, Matin SF, Kamat AM, Grossman HB, Nogueras-González GM, Urbauer DL, Dinney CP. Age and Body Mass Index Are Independent Risk Factors for the Development of Postoperative Paralytic Ileus After Radical Cystectomy. Urology 76(6):1419-24, 2010. e-Pub 2010. PMID: 20472264.
- Metwalli AR, Khanbolooki S, Jinesh G, Sundi D, Shah JB, Shrader M, Choi W, Lashinger LM, Chunduru S, McConkey DJ, McKinlay M, Kamat AM. Smac mimetic reverses resistance to TRAIL and chemotherapy in human urothelial cancer cells. Cancer Biol Ther 10(9):885-92, 2010. e-Pub 2010. PMID: 20814238.
- Caraway NP, Khanna A, Fernandez RL, Payne L, Bassett RL, Zhang HZ, Kamat AM, Katz RL. Fluorescence in situ hybridization for detecting urothelial carcinoma: a clinicopathologic study. Cancer Cytopathol 118(5):259-68, 2010. e-Pub 2010. PMID: 20665656.
- Xu AD, Ng CS, Kamat AM, Grossman HB, Dinney C, Sandler CM. Significance of upper urinary tract urothelial thickening and filling defect seen on MDCT urography in patients with a history of urothelial neoplasms. AJR Am J Roentgenol 195(4):959-65, 2010. PMID: 20858825.
- Chen M, Hildebrandt MA, Clague J, Kamat AM, Picornell A, Chang J, Zhang X, Izzo J, Yang H, Lin J, Gu J, Chanock S, Kogevinas M, Rothman N, Silverman DT, Garcia-Closas M, Grossman HB, Dinney CP, Malats N, Wu X. Genetic Variations in the Sonic Hedgehog Pathway Affect Clinical Outcomes in Non-Muscle-Invasive Bladder Cancer. Cancer Prev Res (Phila) 3(10):1235-45, 2010. e-Pub 2010. PMID: 20858759.
- Matin SF, Kamat AM, Grossman HB. High-frequency endoluminal ultrasonography as an aid to the staging of upper tract urothelial carcinoma: imaging findings and pathologic correlation. J Ultrasound Med 29(9):1277-84, 2010. PMID: 20733182.
- Taylor JM, Spiess PE, Kassouf W, Munsell MF, Kamat AM, Dinney CP, Grossman HB, Pisters LL. Management of urethral recurrence after orthotopic urinary diversion. BJU Int 106(1):56-61, 2010. e-Pub 2009. PMID: 20002676.
- Matin SF, Margulis V, Kamat AM, Wood CG, Grossman HB, Brown GA, Dinney CP, Millikan R, Siefker-Radtke AO. Incidence of downstaging and complete remission after neoadjuvant chemotherapy for high-risk upper tract transitional cell carcinoma. Cancer 116(13):3127-34, 2010. PMID: 20564621.
- Shariat SF, Svatek RS, Tilki D, Skinner E, Karakiewicz PI, Capitanio U, Bastian PJ, Volkmer BG, Kassouf W, Novara G, Fritsche HM, Izawa JI, Ficarra V, Lerner SP, Sagalowsky AI, Schoenberg MP, Kamat AM, Dinney CP, Lotan Y, Marberger MJ, Fradet Y. International validation of the prognostic value of lymphovascular invasion in patients treated with radical cystectomy. BJU Int 105(10):1402-12, 2010. e-Pub 2010. PMID: 20132195.
- Carthon BC, Wolchok JD, Yuan J, Kamat AM, Ng Tang DS, Sun J, Ku G, Troncoso P, Logothetis CJ, Allison JP, Sharma P. Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial. Clin Cancer Res 16(10):2861-71, 2010. e-Pub 2010. PMID: 20460488.
- Davis JW, Kamat AM, Munsell M, Pettaway C, Pisters L, Matin S. Initial experience of teaching robot-assisted radical prostatectomy to surgeons-in-training: can training be evaluated and standardized?. BJU Int 105(8):1148-54, 2010. e-Pub 2009. PMID: 19874300.
- Chiong E, Hegarty PK, Davis JW, Kamat AM, Pisters LL, Matin SF. Port-site Hernias Occurring After the Use of Bladeless Radially Expanding Trocars. Urology 75(3):574-80, 2010. e-Pub 2009. PMID: 19854489.
- Cho SD, Lee SO, Chintharlapalli S, Abdelrahim M, Khan S, Yoon K, Kamat AM, Safe S. Activation of Nerve Growth Factor-Induced B{alpha} by Methylene-Substituted Diindolylmethanes in Bladder Cancer Cells Induces Apoptosis and Inhibits Tumor Growth. Mol Pharmacol 77(3):396-404, 2010. e-Pub 2009. PMID: 20023005.
- Svatek RS, Fisher MB, Matin SF,Kamat AM, Grossman HB, Nogueras-González GM, Urbauer DL, Kennedy KA, Dinney CP. Risk Factor Analysis in a Contemporary Cystectomy Cohort Using Standardized Reporting Methodology and Adverse Event Criteria. J Urol 183(3):929-34, 2010. e-Pub 2010. PMID: 20083264.
- Fritsche HM, Burger M, Svatek RS, Jeldres C, Karakiewicz PI, Novara G, Skinner E, Denzinger S, Fradet Y, Isbarn H, Bastian PJ, Volkmer BG, Montorsi F, Kassouf W, Tilki D, Otto W, Capitanio U, Izawa JI, Ficarra V, Lerner S, Sagalowsky AI, Schoenberg M, Kamat AM, Dinney CP, Lotan Y, Shariat SF. Characteristics and Outcomes of Patients with Clinical T1 Grade 3 Urothelial Carcinoma Treated with Radical Cystectomy: Results from an International Cohort. Eur Urol 57(2):300-9, 2010. e-Pub 2009. PMID: 19766384.
- Tharakan ST, Inamoto T, Sung B, Aggarwal BB, Kamat AM. Curcumin Potentiates the Antitumor Effects of Gemcitabine in an Orthotopic Model of Human Bladder Cancer through Suppression of Proliferative and Angiogenic Biomarkers. Biochem Pharmacol 79(2):218-28, 2010. e-Pub 2009. PMID: 19682434.
- Inamoto T, Czerniak BA, Dinney CP, Kamat AM. Cytoplasmic mislocalization of the orphan nuclear receptor Nurr1 is a prognostic factor in bladder cancer. Cancer 2(116):340-346, 2010. PMID: 19908257.
- Kulkarni GS, Hakenberg OW, Gschwend JE, Thalmann G, Kassouf W, Kamat AM, Zlotta A. An Updated Critical Analysis of the Treatment Strategy for Newly Diagnosed High-grade T1 (Previously T1G3) Bladder Cancer. Eur Urol 57(1):60-70, 2010. e-Pub 2009. PMID: 19740595.
- Kamat AM, Tharakan ST, Sung B, Aggarwal BB. Curcumin potentiates the antitumor effects of Bacillus Calmette-Guerin against bladder cancer through the downregulation of NF-kappaB and upregulation of TRAIL receptors. Cancer Res 69(23):8958-66, 2009. e-Pub 2009. PMID: 19903839.
- Fisher MB, Svatek RS, Hegarty PK, McGinniss JE, Hightower C, Grossman HB, Kamat AM, Dinney CP, Matin SF. Cardiac history and risk of post-cystectomy cardiac complications. Urology 74(5):1085-9, 2009. e-Pub 2009. PMID: 19758689.
- Guo CC, Gomez E, Tamboli P, Bondaruk JE, Kamat AM, Bassett R, Dinney CP, Czerniak BA. Squamous cell carcinoma of the urinary bladder: a clinicopathologic and immunohistochemical study of 16 cases. Hum Pathol 40(10):1448-52, 2009. e-Pub 2009. PMID: 19454359.
- Lotan Y, Kamat AM, Porter MP, Robinson VL, Shore N, Jewett M, Schelhammer PF, deVere White R, Quale D, Lee CT. Key concerns about the current state of bladder cancer: a position paper from the Bladder Cancer Think Tank, the Bladder Cancer Advocacy Network, and the Society of Urologic Oncology. Cancer 115(18):4096-103, 2009. PMID: 19536899.
- Lin J, Kamat AM, Gu J, Chen M, Dinney CP, Forman MR, Wu X. Dietary intake of vegetables and fruits and the modification effects of GSTM1 and NAT2 genotypes on bladder cancer risk. Cancer Epidemiol Biomarkers Prev 18(7):2090-7, 2009. e-Pub 2009. PMID: 19549811.
- Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Qiao W, Thall PF, Dinney CP, Millikan RE. Phase II Clinical Trial of Neoadjuvant Alternating Doublet Chemotherapy With Ifosfamide/Doxorubicin and Etoposide/Cisplatin in Small-Cell Urothelial Cancer. J Clin Oncol 27(16):2592-7, 2009. e-Pub 2009. PMID: 19414678.
- Jain M, Matin SF, Kamat AM. Inferior Vena Cava Atresia Associated with von Hippel-Lindau Masquerading as Metastatic Testicular Cancer. Curr Urol 2(4):214-216, 2009. e-Pub 2009.
- Chen H, Liakou CI, Kamat A, Pettaway C, Ward JF, Tang DN, Sun J, Jungbluth AA, Troncoso P, Logothetis C, Sharma P. Anti-CTLA-4 therapy results in higher CD4+ICOShi T cell frequency and IFN-gamma levels in both nonmalignant and malignant prostate tissues. Proc Natl Acad Sci U S A 106(8):2729-34, 2009. e-Pub 2009. PMID: 19202079.
- Svatek RS, Spiess PE, Sundi D, Tu SM, Tannir NM, Brown GA, Kamat AM, Wood CG, Pisters LL. Long-term outcome for men with teratoma found at postchemotherapy retroperitoneal lymph node dissection. Cancer 115(6):1310-7, 2009. e-Pub 2009. PMID: 19156903.
- Margulis V, Shariat SF, Matin SF, Kamat AM, Zigeuner R, Kikuchi E, Lotan Y, Weizer A, Raman JD, Wood CG, Wood CG. Outcomes of radical nephroureterectomy: A series from the Upper Tract Urothelial Carcinoma Collaboration. Cancer 115(6):1224-33, 2009. e-Pub 2009. PMID: 19156917.
- Kassouf W, Agarwal PK, Grossman HB, Leibovici D, Munsell MF, Siefker-Radtke A, Pisters LL, Swanson DA, Dinney CP, Kamat AM. Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy. Urology 73(1):147-52, 2009. e-Pub 2008. PMID: 18848348.
- Inamoto T, Papineni S, Chintharlapalli S, Cho SD, Safe S, Kamat AM. 1,1-Bis(3'-indolyl)-1-(p-chlorophenyl)methane activates the orphan nuclear receptor Nurr1 and inhibits bladder cancer growth. Mol Cancer Ther 7(12):3825-33, 2008. PMID: 19074857.
- Liakou CI, Kamat AM, Tang DN, Chen H, Sun J, Troncoso P, Logothetis C, Sharma P. CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients. Proc Natl Acad Sci U S A 105(39):14987-92, 2008. e-Pub 2008. PMID: 18818309.
- Kassouf W, Spiess PE, Brown GA, Liu P, Grossman HB, Dinney CP, Kamat AM. Prostatic Urethral Biopsy Has Limited Usefulness in Counseling Patients Regarding Final Urethral Margin Status During Orthotopic Neobladder Reconstruction. J Urol 180(1):164-7; discussion 167, 2008. e-Pub 2008. PMID: 18485384.
- Cárdenas-Turanzas M, Cooksley C, Kamat AM, Pettaway CA, Elting LS. Gender and age differences in blood utilization and length of stay in radical cystectomy: a population-based study. Int Urol Nephrol 40(4):893-9, 2008. e-Pub 2008. PMID: 18317944.
- Kassouf W, Agarwal PK, Herr HW, Munsell MF, Spiess PE, Brown GA, Pisters L, Grossman HB, Dinney CP, Kamat AM. Lymph node density is superior to TNM nodal status in predicting disease-specific survival after radical cystectomy for bladder cancer: analysis of pooled data from MDACC and MSKCC. J Clin Oncol 26(1):121-6, 2008. PMID: 18165646.
- Spiess PE, Pisters LL, Liu P, Pettaway CA, Kamat AM, Gomez JA, Tannir NM. Malignant transformation of testicular teratoma: A chemoresistant phenotype. Urol Oncol 26(6):595-9, 2008. e-Pub 2008. PMID: 18367105.
- Sabichi AL, Lerner SP, Atkinson EN, Grossman HB, Caraway NP, Dinney CP, Penson DF, Matin SF, Kamat AM, Pisters LL, Lin DW, Katz RL, Brenner DE, Hemstreet GP, Wargo M, Bleyer A, Sanders WH, Clifford JL, Parnes HL, Lippman SM. Phase III Prevention Trial of Fenretinide in Patients with Resected Non Muscle-Invasive Bladder Cancer. Clin Cancer Res 14(1):224-229, 2008. PMID: 18172274.
- Spiess PE, Tannir NM, Tu SM, Brown GA, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Viable germ cell tumor at postchemotherapy retroperitoneal lymph node dissection: can we predict patients at risk of disease progression?. Cancer 110(12):2700-2708, 2007. PMID: 17948916.
- Wright JL, Black PC, Brown GA, Porter MP, Kamat AM, Dinney CP, Lin DW. Differences in survival among patients with sarcomatoid carcinoma, carcinosarcoma and urothelial carcinoma of the bladder. J Urol 178(6):2302-2306, 2007. e-Pub 2007. PMID: 17936803.
- Caraway NP, Khanna A, Payne L, Kamat AM, Katz RL. Combination of cytologic evaluation and quantitative digital cytometry is reliable in detecting recurrent disease in patients with urinary diversions. Cancer 111(5):323-329, 2007. e-Pub 2007. PMID: 17721991.
- Chen M, Kamat AM, Huang M, Grossman HB, Dinney CP, Lerner SP, Wu X, Gu J. High-order interactions among genetic polymorphisms in nucleotide excision repair pathway genes and smoking in modulating bladder cancer risk. Carcinogenesis 28(10):2160-2165, 2007. e-Pub 2007. PMID: 17728339.
- Jhamb M, Lin J, Ballow R, Kamat AM, Grossman HB, Wu X. Urinary tract diseases and bladder cancer risk: a case-control study. Cancer Causes Control 18(8):839-45, 2007. PMID: 17593531.
- Brown GA, Matin SF, Busby JE, Dinney CP, Grossman HB, Pettaway CA, Munsell MF, Kamat AM. Ability of clinical grade to predict final pathologic stage in upper urinary tract transitional cell carcinoma: implications for therapy. Urology 70(2):252-6, 2007. PMID: 17826484.
- Kassouf W, Spiess PE, Siefker-Radtke A, Swanson D, Grossman HB, Kamat AM, Munsell MF, Guo CC, Czerniak BA, Dinney CP. Outcome and patterns of recurrence of nonbilharzial pure squamous cell carcinoma of the bladder: a contemporary review of The University of Texas M D Anderson Cancer Center experience. Cancer 110(4):764-9, 2007. PMID: 17614317.
- Kamat AM, Dinney CP, Gee JR, Grossman HB, Siefker-Radtke AO, Tamboli P, Detry MA, Robinson TL, Pisters LL. Micropapillary bladder cancer: a review of the University of Texas M. D. Anderson Cancer Center experience with 100 consecutive patients. Cancer 110(1):62-7, 2007. PMID: 17542024.
- Spiess PE, Kassouf W, Brown GA, Kamat AM, Liu P, Gomez JA, Tu SM, Tannir NM, Pisters LL. Surgical management of growing teratoma syndrome: the M. D. Anderson cancer center experience. J Urol 177(4):1330-4; discussion 1334, 2007. PMID: 17382725.
- Kamat AM, Sethi G, Aggarwal BB. Curcumin potentiates the apoptotic effects of chemotherapeutic agents and cytokines through down-regulation of nuclear factor-kappaB and nuclear factor-kappaB-regulated gene products in IFN-alpha-sensitive and IFN-alpha-resistant human bladder cancer cells. Mol Cancer Ther 6(3):1022-30, 2007. PMID: 17363495.
- Kamat AM, Wu X. Statins and the effect of BCG on bladder cancer. N Engl J Med 356(12):1276; author reply 1276-7, 2007. PMID: 17377172.
- Black PC, Kassouf W, Brown GA, Liu P, Kamat AM, Nogueras GM, Munsell MF, Siefker-Radtke A, Millikan RE, Grossman HB, Dinney CP. Variant histology in bladder cancer-experience in 1246 patients undergoing cystectomy. J Urol 177(4):502, 2007.
- Spiess PE, Tannir NM, Brown GA, Liu P, Kamat AM. Recurrence in patients with PNO at RPLND: can we predict which patients are at risk?. J Urol 177(4):330, 2007.
- Spiess PE, Brown GA, Tannir NM, Tu Shi-Ming, Liu P, Kamat AM. Predicting disease progression in patients with viable tumor at post-chemotherapy rplnd. JUrol 177(4):278, 2007.
- Spiess PE, Brown GA, Liu P, Tu SM, Tannir NM, Evans JG, Kamat AM, Kassouf W, Pisters LL. Recurrence pattern and proposed surveillance protocol following post-chemotherapy retroperitoneal lymph node dissection. J Urol 177(1):131-8, 2007. PMID: 17162023.
- Spiess PE, Kassouf W, Steinberg JR, Tuziak T, Hernandez M, Tibbs RF, Czerniak B, Kamat AM, Dinney CP, Grossman HB. Review of the M.D. Anderson experience in the treatment of bladder sarcoma. Urol Oncol 25(1):38-45, 2007. PMID: 17208137.
- Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Siefker-Radtke A, Dinney CP, Kamat AM. P0 Stage at Radical Cystectomy for Bladder Cancer is Associated with Improved Outcome Independent of Traditional Clinical Risk Factors. Eur Urol 52(3):769-776, 2007. PMID: 17434254.
- Brown GA, Busby JE, Wood CG, Pisters LL, Dinney CP, Swanson DA, Grossman HB, Pettaway CA, Munsell MF, Kamat AM, Matin SF. Nephroureterectomy for treating upper urinary tract transitional cell carcinoma: Time to change the treatment paradigm?. BJU Int 98(6):1176-80, 2006. PMID: 17125474.
- Papageorgiou A, Kamat A, Benedict WF, Dinney C, McConkey DJ. Combination therapy with IFN-alpha plus bortezomib induces apoptosis and inhibits angiogenesis in human bladder cancer cells. Mol Cancer Ther 5(12):3032-41, 2006. PMID: 17172406.
- Evans JG, Spiess PE, Kamat AM, Wood CG, Hernandez M, Pettaway CA, Dinney CP, Pisters LL. Chylous ascites after post-chemotherapy retroperitoneal lymph node dissection: review of the M. D. Anderson experience. J Urol 176(4 Pt 1):1463-7, 2006. PMID: 16952661.
- Kassouf W, Highshaw R, Nelkin GM, Dinney CP, Kamat AM. Vitamins C and K3 sensitize human urothelial tumors to gemcitabine. J Urol 176(4 Pt 1):1642-7, 2006. PMID: 16952707.
- Kassouf W, Leibovici D, Luongo T, Munsell MF, Vakar F, Dinney CP, Grossman HB, Kamat AM. Relevance of extracapsular extension of pelvic lymph node metastasis in patients with bladder cancer treated in the contemporary era. Cancer 107(7):1491-5, 2006. PMID: 16894527.
- Spiess PE, Brown GA, Liu P, Tannir NM, Tu SM, Evans JG, Czerniak B, Kamat AM, Pisters LL. Predictors of outcome in patients undergoing postchemotherapy retroperitoneal lymph node dissection for testicular cancer. Cancer 107(7):1483-90, 2006. PMID: 16944541.
- Spiess PE, Brown GA, Pisters LL, Liu P, Tu SM, Evans JG, Kamat AM, Black P, Tannir NM. Viable malignant germ cell tumor in the postchemotherapy retroperitoneal lymph node dissection specimen: can it be predicted using clinical parameters?. Cancer 107(7):1503-10, 2006. PMID: 16944534.
- Strom SS, Kamat AM, Gruschkus SK, Gu Y, Wen S, Cheung MR, Pisters LL, Lee AK, Rosser CJ, Kuban DA. Influence of obesity on biochemical and clinical failure after external-beam radiotherapy for localized prostate cancer. Cancer 107(3):631-9, 2006. PMID: 16802288.
- Kassouf W, Leibovici D, Munsell MF, Dinney CP, Grossman HB, Kamat AM. Evaluation of the relevance of lymph node density in a contemporary series of patients undergoing radical cystectomy. J Urol 176(1):53-7; discussion 57, 2006. PMID: 16753366.
- Rosser CJ, Kamat AM, Pendleton J, Robinson TL, Pisters LL, Swanson DA, Babaian RJ. Impact of fellowship training on pathologic outcomes and complication rates of radical prostatectomy. Cancer 107(1):54-9, 2006. PMID: 16708356.
- Kassouf W, Swanson D, Kamat AM, Leibovici D, Siefker-Radtke A, Munsell MF, Grossman HB, Dinney CP. Partial cystectomy for muscle invasive urothelial carcinoma of the bladder: a contemporary review of the M. D. Anderson Cancer Center experience. J Urol 175(6):2058-62, 2006. PMID: 16697803.
- Rosser CJ, Kamat AM, Wang X, Do KA, Naya Y, Hoover DC, Troncoso P, Sanches-Ortiz RF, Pisters LL. Biochemical disease-free survival in men younger than 60 years with prostate cancer treated with radical prostatectomy. Urology 67(4):769-73, 2006. e-Pub 2006. PMID: 16584762.
- Canfield SE, Kamat AM, Sánchez-Ortiz RF, Detry M, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): the impact of aggressive surgical resection on patient outcome. J Urol 175(3 Pt 1):864-9, 2006. PMID: 16469567.
- Busby JE, Brown GA, Tamboli P, Kamat AM, Dinney CP, Grossman HB, Matin SF. Upper urinary tract tumors with nontransitional histology: a single-center experience. Urology 67(3):518-23, 2006. PMID: 16527570.
- Kamat AM, Gee JR, Dinney CP, Grossman HB, Swanson DA, Millikan RE, Detry MA, Robinson TL, Pisters LL. The case for early cystectomy in the treatment of nonmuscle invasive micropapillary bladder carcinoma. J Urol 175(3 Pt 1):881-5, 2006. PMID: 16469571.
- Spiess PE, Kassouf W, Brown G, Highshaw R, Wang X, Do KA, Kamat AM, Czerniak B, Dinney CP, Grossman HB. Immediate versus staged urethrectomy in patients at high risk of urethral recurrence: is there a benefit to either approach?. Urology 67(3):466-71, 2006. PMID: 16527559.
- Dhanani NN, Kamat AM. Treatment of bladder cancer in cardiac transplant patients. Int Urol Nephrol 38(3-4):477-9, 2006. PMID: 17115247.
- Kassouf W, Chintharlapalli S, Abdelrahim M, Nelkin G, Safe S, Kamat AM. Inhibition of bladder tumor growth by 1,1-bis(3'-indolyl)-1-(p-substitutedphenyl)methanes: a new class of peroxisome proliferator-activated receptor gamma agonists. Cancer Res 66(1):412-8, 2006. PMID: 16397256.
- Kamat AM, Nelkin GM. Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology 66(6):1209-12, 2005. PMID: 16360444.
- Leibovici D, Kamat AM, Pettaway CA, Pagliaro L, Rosser CJ, Logothetis C, Pisters LL. Cystoprostatectomy for effective palliation of symptomatic bladder invasion by prostate cancer. J Urol 174(6):2186-90, 2005. PMID: 16280761.
- Kamat AM, Jacobsohn KM, Troncoso P, Shen Y, Wen S, Babaian RJ. Validation of criteria used to predict extraprostatic cancer extension: a tool for use in selecting patients for nerve sparing radical prostatectomy. J Urol 174(4 Pt 1):1262-5, 2005. PMID: 16145389.
- Mohamedali KA, Kedar D, Sweeney P, Kamat A, Davis DW, Eve BY, Huang S, Thorpe PE, Dinney CP, Rosenblum MG. The vascular-targeting fusion toxin VEGF121/rGel inhibits the growth of orthotopic human bladder carcinoma tumors. Neoplasia 7(10):912-20, 2005. PMID: 16242074.
- Cheung R, Kamat AM, de Crevoisier R, Allen PK, Lee AK, Tucker SL, Pisters L, Babaian RJ, Kuban D. Outcome of salvage radiotherapy for biochemical failure after radical prostatectomy with or without hormonal therapy. Int J Radiat Oncol Biol Phys 63(1):134-40, 2005. PMID: 16111581.
- Shapiro A, Vakar F, Kamat AM. Diffuse granulomatous mesenteric disease caused by intravesical bacillus Calmette-Guerin instillation masquerading as peritoneal carcinomatosis. Urol Oncol 23(5):352-3, 2005. PMID: 16144670.
- Rosser CJ, Kamat AM, Wang X, Do KA, Sanchez-Ortiz RF, Kuban DA, Lee AK, Cheung R, Chichakli R, Pisters LL. Is patient age a factor in the occurrence of prostate-specific antigen bounce phenomenon after external beam radiotherapy for prostate cancer?. Urology 66(2):327-31, 2005. PMID: 16040084.
- Kamat AM, Carpenter SM, Czerniak BA, Pisters LL. Metastatic penile cancer in a young Caucasian male: impact of delayed diagnosis. Urol Oncol 23(2):130-1, 2005. PMID: 15869998.
- Cheung R, Tucker SL, Lee AK, de Crevoisier R, Dong L, Kamat A, Pisters L, Kuban D. Dose-response characteristics of low- and intermediate-risk prostate cancer treated with. Int J Radiat Oncol Biol Phys 61(4):993-1002, 2005. PMID: 15752878.
- Leibovici D, Kamat AM, Do KA, Pettaway CA, Ng CS, Evans RB, Rodriguez-Bigas M, Skibber J, Wang X, Pisters LL. Transrectal ultrasound versus magnetic resonance imaging for detection of rectal wall invasion by prostate cancer. Prostate 62(1):101-4, 2005. PMID: 15389800.
- Cheung R, Tucker SL, Lee AL, Dong L, Kamat A, Pisters L, Kuban DA. Assessing the impact of an alternative biochemical failure definition on radiation dose response for high-risk prostate cancer treated with external beam radiotherapy. Int J Radiat Oncol Biol Phys 61(1):14-19, 2005. PMID: 15629589.
- Rosser CJ, Kuban DA, Lee SJ, Levy LB, Pettaway C, Kamat AM, Chichakli R, Lee A, Cheung RM, Sanchez-Ortiz R, Pisters LL. Racial influence on biochemical disease-free survival in men treated with external-beam radiotherapy for localized prostate cancer. J Natl Med Assoc 96(7):939-44, 2004. PMID: 15253325.
- Kamat AM, Rosser CJ, Levy LB, Chichakli R, Lee AK, Cheung MR, Pisters LL. Rise in serum PSA of 1.5 ng/mL above 24-month nadir after external beam radiotherapy is predictive of biochemical failure. Urology 63(6):1132-7, 2004. PMID: 15183966.
- Kamat AM, Plager C, Tamboli P, Tran N, Pettaway CA. Metastatic epithelioid hemangioendothelioma of the penis managed with surgery and interferon-alpha. J Urol 171(5):1886-7, 2004. PMID: 15076299.
- Kamat AM, Karashima T, Davis DW, Lashinger L, Bar-Eli M, Millikan R, Shen Y, Dinney CP, McConkey DJ. The proteasome inhibitor bortezomib synergizes with gemcitabine to block the growth of human 253JB-V bladder tumors in vivo. Mol Cancer Ther 3(3):279-90, 2004. PMID: 15026548.
- Kamat AM, Lamm DL. Antitumor activity of common antibiotics against superficial bladder cancer. Urology 63(3):457-60, 2004. PMID: 15028437.
- Kamat AM, Shock RP, Naya Y, Rosser CJ, Slaton JW, Pisters LL. Prognostic value of body mass index in patients undergoing nephrectomy for localized renal tumors. Urology 63(1):46-50, 2004. PMID: 14751346.
- Kamat AM, Babaian K, Cheung MR, Naya Y, Huang SH, Kuban D, Babaian RJ. Identification of factors predicting response to adjuvant radiation therapy in patients with positive margins after radical prostatectomy. J Urol 170(5):1860-3, 2003. PMID: 14532793.
- Kamat AM, Huang SF, Bermejo CE, Rosser CJ, Pettaway CA, Pisters PW, Guitreau D, Pisters LL. Total pelvic exenteration: effective palliation of perineal pain in patients with locally recurrent prostate cancer. J Urol 170(5):1868-71, 2003. PMID: 14532795.
- Rosser CJ, Kuban DA, Levy LB, Pettaway CA, Chichakli R, Kamat AM, Sanchez-Ortiz RF, Pisters LL. Clinical features and treatment outcome of Hispanic men with prostate cancer following external beam radiotherapy. J Urol 170(5):1856-9, 2003. PMID: 14532792.
- Kamat A, York T, Debord J. Anastomotic fistula after ileal loop urinary diversion presenting as persistent urethral drainage. J Urol 165(3):906-907, 2001. PMID: 11176505.
- Kamat AM, DeHaven JI, Lamm DL. Quinolone antibiotics: a potential adjunct to intravesical chemotherapy for bladder cancer. Urology 54(1):56-61, 1999. PMID: 10414727.
Invited Articles
- Willis D, Kamat AM. Nonurothelial bladder cancer and rare variant histologies. Hematol Oncol Clin North Am 29(2):237-52, viii, 2015. e-Pub 2015. PMID: 25836932.
- Apolo AB, Hoffman V, Kaag MG, Latini DM, Lee CT, Rosenberg JE, Knowles M, Theodorescu D, Czerniak BA, Efstathiou JA, Albert ML, Sridhar SS, Margulis V, Matin SF, Galsky MD, Hansel D, Kamat AM, Flaig TW, Smith AB, Messing E, Zipursky Quale D, Lotan Y. Summary of the 8th Annual Bladder Cancer Think Tank: Collaborating to move research forward. Urol Oncol 33(2):53-64, 2015. e-Pub 2014. PMID: 25065704.
- Nawroth R, Goebell PJ, Kamat AM, Kiemeney LA, Schmitz-Dräger BJ. Current concepts--future needs: the 10th Annual Meeting of the International Bladder Cancer Network (IBCN) in Nijmegen, The Netherlands, September 20th to 22nd, 2012. Urol Oncol 32(7):1049-50, 2014. e-Pub 2014. PMID: 25443142.
- Porten SP, Willis D, Kamat AM. Variant histology: role in management and prognosis of nonmuscle invasive bladder cancer. Curr Opin Urol. e-Pub 2014. PMID: 24921905.
- Jinesh GG, Willis DL, Kamat AM. Bladder Cancer Stem Cells: Biological and Therapeutic Perspectives. Curr Stem Cell Res Ther. e-Pub 2013. PMID: 24236543.
- Svatek RS, Rosenberg JE, Galsky MD, Lee CT, Latini DM, Bochner BH, Weizer AZ, Apolo AB, Sridhar SS, Kamat AM, Hansel D, Flaig TW, Smith ND, Lotan Y. Summary of the 6th annual bladder cancer think tank: New directions in urologic research. Urol Oncol 31(7):968-73, 2013. e-Pub 2012. PMID: 22300756.
- Willis DL, Porten SP, Kamat AM. Should histologic variants alter definitive treatment of bladder cancer?. Curr Opin Urol 23(5):435-43, 2013. e-Pub 2013. PMID: 23880739.
- Shah JB, Kamat AM. Strategies for optimizing bacillus calmette-guerin. Urol Clin North Am 40(2):211-8, 2013. PMID: 23540779.
- Kamat AM. Is repeat transurethral resection needed for minimally invasive t1 urothelial cancer?. J Urol 186(3):788-9, 2011. e-Pub 2011. PMID: 21794877.
- Kamat AM, Mathew P. Bladder cancer: imperatives for personalized medicine. Oncology (Williston Park) 25(10):951-8, 960, 2011. PMID: 22010395.
- Dickstein RJ, Kamat AM. Contemporary management of locally invasive bladder cancer. Oncology (Williston Park) 25(14):1396-405, 2011. PMID: 22329191.
- Tran MN, Goodwin Jinesh G, McConkey DJ, Kamat AM. Bladder cancer stem cells. Curr Stem Cell Res Ther 5(4):387-95, 2010. PMID: 20955163.
- Kassouf W, Kamat AM, Zlotta A, Bochner BH, Moore R, So A, Izawa J, Rendon RA, Lacombe L, Aprikian AG. Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy. Can Urol Assoc J 4(3):168-73, 2010. PMID: 20514279.
- Robinson VL, Porter M, Messing E, Fradet Y, Kamat AM, Lotan Y. BCAN Think Tank session 2: Molecular detection of bladder cancer: the path to progress. Urol Oncol 28(3):334-7, 2010. PMID: 20439033.
- Lerner SP, Grossman HB, Messing EM, Kibel AS, Stephenson A, Gee JR, O'Donnell MA, Reid RD, Kamat AM, Parnes HL, House MG. BCAN Think Tank session 3: Prevention of bladder cancer. Urol Oncol 28(3):338-42, 2010. PMID: 20439034.
- Kamat AM, Lotan YR. Perioperative intravesical therapy after transurethral resection for bladder cancer. J Urol 183(1):19-20, 2010. PMID: 19913827.
- Karam JA, Kamat AM. Optimal timing of chemotherapy and cystectomy. F1000 Med Rep 2, 2010. e-Pub 2010. PMID: 20948836.
- Inamoto T, Shah JB, Kamat AM. Friend or foe? Role of peroxisome proliferator-activated receptor-gamma in human bladder cancer. Urol Oncol 27(6):585-91, 2009. e-Pub 2009. PMID: 19162510.
- Svatek RS, Kamat AM, Dinney CP. Novel therapeutics for patients with non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 9(6):807-13, 2009. PMID: 19496717.
- Martin FM, Kamat AM. Definition and management of patients with bladder cancer who fail BCG therapy. Expert Rev Anticancer Ther 9(6):815-20, 2009. PMID: 19496718.
- McConkey DJ, Choi W, Marquis L, Martin F, Williams MB, Shah J, Svatek R, Das A, Adam L, Kamat AM, Siefker-Radtke A, Dinney C. Role of epithelial-to-mesenchymal transition (EMT) in drug sensitivity and metastasis in bladder cancer. Cancer Metastasis Rev 28(3-4):335-44, 2009. PMID: 20012924.
- Hegarty PK, Kamat AM. Management of bladder cancer. Minerva Urol Nefrol 60(4):255-64, 2008. PMID: 18923362.
- La Rochelle J, Kamat AM, Grossman HB, Pantuck A. Chemoprevention of bladder cancer. BJU Int 102(9 Pt B):1274-8, 2008. PMID: 19035892.
- Agarwal PK, Black PC, Kamat AM. Considerations on the use of diagnostic markers in management of patients with bladder cancer. World J Urol 26(1):39-44, 2008. e-Pub 2007. PMID: 18092171.
- Agarwal PK, Kamat AM. Pros and cons of radical cystectomy in the treatment of T1G3 bladder cancer. Indian J Urol 24(1):77-83, 2008. PMID: 19468365.
- Kamat AM, Dinney CP. A combination of intravesical BCG [corrected] and [corrected] electromotive mitomycin for high-risk superficial bladder cancer. Nat Clin Pract Urol 3(9):472-3, 2006. PMID: 16964186.
- Metwalli AR, Kamat AM. Controversial issues and optimal management of stage T1G3 bladder cancer. Expert Rev Anticancer Ther 6(8):1283-94, 2006. PMID: 16925494.
- Busby JE, Kamat AM. Chemoprevention for bladder cancer. J Urol 176(5):1914-20, 2006. PMID: 17070211.
- Brassell SA, Kamat AM. Contemporary Intravesical Treatment Options for Urothelial Carcinoma of the bladder. J Natl Compr Canc Netw 4(10):1027-1036, 2006. PMID: 17112451.
- Dinney CP, McConkey DJ, Millikan RE, Wu X, Bar-Eli M, Adam L, Kamat AM, Siefker-Radtke AO, Tuziak T, Sabichi AL, Grossman HB, Benedict WF, Czerniak B. Focus on bladder cancer. Cancer Cell 6(2):111-6, 2004. PMID: 15324694.
- Herring JC, Kamat AM. Treatment of muscle-invasive bladder cancer: progress and new challenges. Expert Rev Anticancer Ther 4(6):1047-1056, 2004. PMID: 15606332.
- Kassouf W, Kamat AM. Current state of immunotherapy for bladder cancer. Expert Rev Anticancer Ther 4(6):1283-1294, 2004. PMID: 15606331.
- Kamat AM. Chemoprevention of superficial bladder cancer. Expert Rev Anticancer Ther 3(6):799-808, 2003. PMID: 14686702.
- Kamat AM, Dinney CPN. Molecular aspects of metastases in bladder cancer. Urol Integ 8(2):180-189, 2003.
- Kamat AM, Lamm DL. Chemoprevention of bladder cancer. Urol Clin North Am 29(1):1-12, 2002. PMID: 12109342.
- Kamat AM, Lamm DL. Immunotherapy for bladder cancer. Curr Urol Rep 2(1):62-69, 2001. PMID: 12084297.
- Kamat AM, Lamm DL. Intravesical therapy for bladder cancer. Urology 55(2):161-168, 2000. PMID: 10688071.
- Kamat AM, Lamm DL. Current trends in intravesical therapy for bladder cancer. Contemporary Urology 12(8):64-88, 2000.
- Kamat AM, Lamm DL. Diet and nutrition in urologic cancer. W V Med J 96(3):449-454, 2000. PMID: 14619137.
- Kamat AM, Lamm DL. Chemoprevention of urological cancer. J Urol 161(6):1748-60, 1999. PMID: 10332429.
- Kamat AM, Lamm DL. Role of BCG in treatment of superficial bladder cancer. Indian Journal of Urology 16(1):1-9, 1999.
- Kamat AM, Lamm DL. Intravesical therapy for superficial bladder cancer. Inf Urol 12(2):37-45, 1999.
Manuals, Teaching Aids, Other Teaching Publications
- Kamat AM. When to Use Intravesical Therapy for Bladder Cancer. Renal & Urology News, 2007.
- Kamat AM. Prostate Cancer Guidelines. HealthGate: Burlington, MA, 2005.
- Kamat AM. Bladder Cancer Options - State of the Art Patient Care, 2005.
- Kamat AM. BCG Immunotherapy: Bladder Cancer and Beyond. CME Supplement to "Renal & Urology News", 2004.
Other Articles
- Kamat AM, Agarwal P, Bivalacqua T, Chisolm S, Daneshmand S, Doroshow JH, Efstathiou JA, Galsky M, Iyer G, Kassouf W, Shah J, Taylor J, Williams SB, Quale DZ, Rosenberg JE Collaborating to Move Research Forward: Proceedings of the 10th Annual Bladder Cancer Think Tank. Bladder Cancer 2(2):203-213, 2016. PMID: 27376139.
Editorials
- Seiler R, Black PC, Williams SB, Goebell PJ, Kamat AM, Nawroth R, Schmitz-Dräger BJ. Editorial: Bladder cancer within the focus of basic and clinical research. Sixth IBCN Seminars Series. Urol Oncol 37(11):815-817, 2019. PMID: 31377169.
- Black PC, Goebell PJ, Kamat AM, Nawroth R, Seiler R, Williams SB, Schmitz-Dräger BJ. Editorial: Basic research in bladder cancer - refining the tools. 3rd IBCN seminars series1. Urol Oncol. PMID: 30683454.
- Kamat AM, Gontero P. Editorial comment. Curr Opin Urol 28(6):555-556, 2018. PMID: 30256260.
- Morales EE, Aggarwal BB, Kamat AM. Natural Compounds Targeting STAT3 Mediated Inflammation. Eur Urol 69(3):405-6, 2016. PMID: 26454706.
- Williams SB, Kamat AM. Optimal Management of Non-Muscle Invasive Micropapillary Variant Urothelial Carcinoma: Possibility For Missed Chance at Cure?. BJU Int. PMID: 26917454.
- Williams SB, Kamat AM, Lamm DL. Pelvic Recurrence Following Radical Cystectomy: A Call to Arms. BJU Int. PMID: 25307493.
- Thomas AZ, Kamat AM. Venous thromboembolism and bleeding risk in bladder cancer. Oncology (Williston Park) 28(10):854-5, 861, 2014. PMID: 25323611.
- Kamat AM, Porten S. Myths and Mysteries Surrounding Bacillus Calmette-Guérin Therapy for Bladder Cancer. Eur Urol. PMID: 24199712.
- Shah JB, Kamat AM. Fluorescence cystoscopy for nonmuscle invasive bladder cancer: is the honeymoon over for the blue light special?. Cancer 117(5):882-3, 2011. PMID: 20960505.
- Kamat AM, Svatek R. Lymphovascular Invasion in Transurethral Resection Specimens as Predictor of Progression and Metastasis in Patients With Newly Diagnosed T1 Bladder Urothelial Cancer. J Urol 182(6):2630; discussion 2631, 2009. PMID: 19836780.
- Kamat AM. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in Patients Treated With Bacillus Calmette-Guerin: The CUETO Scoring Model. J Urol 182(5):2203, 2009. PMID: 19758663.
- Kamat AM. Intravesical BCG for bladder cancer: how much is enough?. Cancer 113(4):674-6, 2008. PMID: 18543323.
- Kamat AM, Fisher MB. Lymph node density: surrogate marker for quality of resection in bladder cancer?. Expert Rev Anticancer Ther 7(6):777-9, Jan-Feb, 2007. PMID: 17555386.
- Kamat AM. Outcome of penile cancer in circumcised men. J Urol 175(2):561, 2006.
- Kamat AM, Dinney CP. Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial. Nat Clin Pract Urol 3(9):472-473, 2006.
- Kamat AM. Neoadjuvant chemotherapy for invasive bladder cancer: a new standard of care?. Am J Clin Onc Rev 2(11):624-637, 2003.
Abstracts
- Kukreja JB, Li R, Seif M, Wang X, Kamat AM, Dinney CP, Pisters LL, Navai N. A comparison of pathologic and intermediate term oncologic outcomes following open and robotic radical cystectomy. Journal of Clinical Oncology 37(7_suppl):440-440, 2019. e-Pub 2019.
- De Wit R, Kulkarni GS, Uchio EM, Krieger LEM, Boormans JL, Roumiguié M, Singer EA, Bajorin DF, Kamat AM, Grivas P, Seo HK, Nishiyama H, Konety BR, Nam K, Kapadia E, Frenkl TL, Balar AV. Pembrolizumab (pembro) for patients (pts) with high-risk (HR) non–muscle invasive bladder cancer (NMIBC) unresponsive to Bacillus Calmette-Guérin (BCG): updated follow-up from KEYNOTE-057. Journal of Clinical Oncology 37(7_suppl):350-350, 2019. e-Pub 2019.
- Ray-Zack MD, Shan Y, Kerr P, Kosarek CD, Hudgins HK, Jazzar U, Kaul S, Kamat AM, Tyler DS, Swanson TA, Mehta HB, Williams SB. Comparing Radical Cystectomy with Trimodal Therapy For Patients Diagnosed With Bladder Cancer: Critical Assessment of Statistical Methodology and Interpretation of Observational Data. Journal of Clinical Oncology 37(7_suppl):373-373, 2019. e-Pub 2019.
- Ray-Zack MD, Shan Y, Kerr P, Kosarek CD, Hudgins HK, Jazaar U, Tyler DS, Freedland SJ, Swanson TA, Baillargeon JG, Hu JC, Kaul S, Kamat AM, Gore JL, Mehta HB, Williams SB. Comparing costs of Radical Cystectomy versus Trimodal Therapy for patients diagnosed with localized muscle-invasive bladder cancer. Journal of Clinical Oncology 37(15_suppl):e16021-e16021, 2019. e-Pub 2019.
- AM Kamat, Shore ND, Hahn NM, Alanee SR, Nishiyama H, Shariat SF, Nam K, Kapadia E, Frenkl TL, Steinberg GD. Bacillus Calmette-Guerin (BCG) with or without pembrolizumab (pembro) for high-risk (HR) non–muscle invasive bladder cancer (NMIBC) that is persistent or recurrent following BCG induction: phase 3 KEYNOTE-676 study. Journal of Clinical Oncology 37(15_suppl):TPS4591-TPS4591, 2019. e-Pub 2019.
- Kamat AM, Chang S, Lee C, Amiel G, Beard T, Fergany A, Kames J, Menon V, Sexton W, Slaton J, Svatek R, Wilson S, Techner L, Bihrle R, Koch M, Steinberg G. Alvimopan, a peripherally acting mu-opioid receptor antagonist, accelerates gastrointestinal recovery and decreases length of hospital stay after radical cystectomy, 2013.
- Kamat AM. BCG Intravesical therpay: improving clinical outcomes and defining BCG failure, 2013.
- Karam JA, Shah JB, Kader AK, Svatek RS, Guo C, Grossman HB, Munsell M, Katz R, Dinney CP, Kamat AM. Prospective trial to identify optimal bladder cancer surveillance protocol: Reducing costs while maximizing sensitivity. 2010 Genitourinary Cancers Symposium, 2010.
- Fernandez, M, Parikh S, Dinney, CP, Grossman HB, Katz R, Matin S, Kamat AM. The Role Of Fish In Upper Urinary Tract Surveillance After Radical Cystectomy For Bladder Cancer. American Urological Association Annual Meeting, 2010. PMID: 21396845.
- Chiong, E, Hegarty, P, Davis, JW, Kamat AM, Pisters, LL, Matin, SF. Port-Site Hernias Occurring After The Use Of Bladeless Radially Expanding. American Urological Association Annual Meeting, 2010.
- Williams M, Pircher T, Zomorrodi M, Mikolajczyk S, Kamat AM. Recovery Of Circulating Tumor Cells In Urothelial Carcinoma Cell Lines Utilizing A Novel Antibody Based Microfluidic Cell Capture Technique. American Urological Association Annual Meeting, 2010.
- Karam J, Shah J, Kader K, Svatek R, Guo C, Grossman HB, Munsell M, Katz R, Dinney C, Kamat AM. Prospective Trial To Identify Optimal Bladder Cancer Surveillance Protocol: Reducing Costs While Maximizing Sensitivity. American Urological Association Annual Meeting, 2010. PMID: 21426474.
- Messetti F, Anderson R, Martinez S, Nogueras Gonzalez G, Katz R, Khanna A, Grossman HB, Dinney C, Kamat AM. Prospective Clinical Trial To Evaluate Markers Of Response To Intravesical Therapy For Bladder Cancer:. American Urological Association Annual Meeting, 2010.
- AO Siefker-Radtke, Kamat AM, DL William, NM Tannir, S Tu, LC Pagliaro, CP Dinney, RE Millikan. A Phase II rendomized four-regimen selection trial incorporating response for sequetial chemotherapy inmetastatic, unresectable urothelial cancer: Final results from the M.D. Anderson Cancer Center. Journal of Clinical Oncology 27(15S):251s, 2009.
- Kassouf W. Agarwal PK, Herr HW, Munsell Mf, Spiess PE, Brown GA, Pisters LL, Grossman HB, Dinney CP, Kamat AM. TNM Nodal status versus lymph node density for prediction of disease-specific survival after radical cystectomy for bladder cancer. J Urol 177(4):551, 2007.
- Spiess PE, Brown GA, Tannir NM, Tu SM, Liu P, Kamat AM, Wood CG, Evans JG, Pisters LL. Predicting Disease Progression in Patients with Viable Tumor at Post Chemotherapy RPLND. American Urological Association Annual Meeting, 2007.
- Spiess PE, Tannir NM, Brown GA, Liu P, Kamat AM, Tu SM, Evans JG, Pister LL,. Recurrence in Patients with pNO at RPLND: Can we Predict which Patients are at Risk?. American Urological Association Annual Meeting, 2007.
- Black PC, Kassouf W, Brown GA, Kamat AM, Nogueras GM, Munsell M, Siefker-Radtke AO, Millikan RE, Grossman HB, Dinney CPN. Variant Histology in Bladder Cancer - Experience in 1246 Patients Undergoing Cystectomy. American Urological Association Annual Meeting, 2007.
- Black PC, Wright JL, Brown GA, Gomez JA, Porter MP, Kamat AM, Dinney CPN, Lin DW. Differences in Survival Between patients with Sarcomatoid Carcinoma, Carcinosarcoma and Transitional Cell Carcinoma of the Bladder. American Urological Association Annual Meeting, 2007.
- Agarwal PK, Kassouf W, Dinney CPN, Munsell MF, Spiess PE, Brown GA, Grossman HB, Herr HW, Kamat AM. TNM Nodal Status Versus Lymph Node Density for Prediction of Disease-Specific Survival After Radical Cystectomy for Bladder Cancer. American Urological Association Annual Meeting, 2007.
- Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Dinney, CPN, Kamat AM. A comparison of performance of TNM staging versus lymph node density in risk stratification of patients undergoing cystectomy for urothelial carcinoma. J Urol 175(4):1251, 2006.
- Siefker-Radtke AO, Kamat AM, Grossman HB, Williams DL, Dinney CPN, Millikan RE. Prospective evidence supporting the utility of neoadjuvant chemotherapy in small cell urothelial cancer: preliminary results from a phase II clinical trial at the M. D. Anderson Cancer Center. J Urol 175(4):1240, 2006.
- Kassouf W, Spiess PE, Brown GA, Munsell MF, Grossman HB, Dinney CPN, Kamat AM. Natural history of bladder cancer in patients with P0 disease at radical cystectomy. J Urol 175(4):1233, 2006.
- Brown GA, Spiess PE, Bassett RL, Siefker-Radtke AO, Grossman HB, Dinney CPN, Kamat AM. Management of primary carcinomas of the male urethra. J Urol 175(4):463, 2006.
- Brown GA, Spiess PE, Bassett RL, Grossman HB, Dinney CPN, Kamat AM. Contemporary management of primary carcinomas of the female urethra. J Urol 175(4):462, 2006.
- Spiess PE, Kassouf W, Brown GA, Kamat AM, Gomez JA, Evans J, Pisters, LL. M. D. Anderson experience in the clinical management of growing teratoma syndrome. J Urol 175(4):448, 2006.
- Spiess P, Evans J, Kamat AM, Wood C, Pettaway C, Dinney C, Pisters L. Chylous Ascites after Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Testicular Cancer. J Urol 173(4):197, 2006.
- Kamat AM, Rosser C, Wen S, Cheung R, Lee A, Putman S, Pisters L. Body Mass Index Does Not Affect Outcome For Men Undergoing External-Beam Radiotherapy For Localized Prostate Cancer. j Urol 173(4):280, 2005.
- Leibovici D, Kassouf W, Kamat AM, Pisters L, Pettaway C, Dinney C. Transurethral tumor resection versus partial cystecomy for bladder preservation for muscle invasive cancer. J Urol 173(4):303, 2005.
- Kassouf W, Safe S, Abdelrahim M, Chintharlapalli S, Nelkin G, Kamat AM. Activity of novel agonists of peroxisome proliferator-activated receptor gamma (PPAR-gamma) against human transitional cell tumors. J Urol 173(4):211, 2005.
- Kassouf W, Leibovici D, Dinney C, Grossman H, Kamat AM. Validation of the concept of lymph node density in a contemporary series of patients. J Urol 173(4):358, 2005.
- Kassouf W, Leibovici D, Zhou X, Dinney C, Grossman H, Siefker-Radtke A, Pisters L, Swanson D, Kamat AM. Significance of lymph node positive disease in patients treated with neoadjuvant chemotherapy: Is adjuvant chemotherapy beneficial?. J Urol 173(4):358, 2005.
- Kamat AM, Gee J, Grossman H, Dinney C, Siefer-Radtke A, Millikan R, Swanson D, Robinson T, Pisters L. Micropapillary Transitional Cell Carcinoma of the Bladder: A Retrospective Review of the Experience with 100 Consecutive Patients. J Urol 173(4):302, 2005.
- Kamat AM, Gee J, Dinney C, Grossman H, Swanson D, Millikan R, Robinson T, Pisters L.. The Case for Early Cystectomy in Non-Muscle-Invasive Micropapillary Transitional Cell Carcinoma of the Bladder. J Urol 173(4):247, 2005. PMID: 16469571.
- Jacobsohn K, Kamat AM, Troncoso P, Shen Y, Wen S, Babaian R. Validation of selection criteria used in predicting extraprostatic cancer extension in patients undergoing nerve-sparing radical prostatectomy. J Urol 173(4):186, 2005.
- Highshaw R, Dinney C, Bermejo C, Nelkin G, Kamat AM. Isolation and Characterization of metastatic variants obtained by orthotopic recycling of the papillary human transitional cell carcinoma (rt4) cell line. J Urol 173(4):159, 2005.
- Highshaw R, Nelkin G, Matin S, Kamat AM. Atorvastatin: Potential For Use as an Anti-Tumor Agent in Bladder Cancer. J Urol 173(4):161, 2005.
- Khanna A, Fernandez R, Payne L, Zhang H, Bekele B, Kamat AM, Caraway N, Katz RL. Telomere length is more highly associated with urothelial cancer in urinary tract cytology specimens than DNA ploidy and bladder recurrence FISH test. American Society of Cytopathology Annual Scientific Meeting, 2004.
- Canfield SE, Kamat AM, Sanchez-Ortiz RF, Swanson DA, Wood CG. Renal cell carcinoma with nodal metastases in the absence of distant metastatic disease (clinical stage TxN1-2M0): predictive factors for survival. J Urol 171(4):1787, 2004.
- Kamat AM, Rosser CJ, Levy LB, Chichakli R, Pisters LL. Fluctuation of > 1.5 ng/ml in serum PSA more than 2 years after external-beam radiotherapy predicts for biochemical failure. J Urol 169(4):1719, 2003.
- Kamat AM, Riggs D, Lamm DL. Anti-tumor activity of common antibiotics against superficial bladder cancer. J Urol 169(4):988, 2003. PMID: 15028437.
- Bermejo C, Dinney C, Kamat AM, Kedar D, Mirabilis R, McConkey D, Elliott W, Bar-Eli M. Downstream signaling pathways and antiangiogenic effects of the pan-erbb tyrosine kinase inhibitor CI-1033 in a human bladder cancer cell line. J Urol 169(4):730, 2003.
- Bermejo C, Sanchez-Ortiz R, Kamat AM, Daliani D, Pettaway C. Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile carcinoma. J Urol 169(4):683, 2003.
- Kamat AM, Kedar D, Bermejo C, Davis D, Radinsky R, Elliott W, Bar-Eli M, McConkey D, Dinney C. CI-1033, a pan-erbB tyrosine kinase antagonist, inhibits the growth of orthotopic bladder cancer tumors via direct effects on receptor phosphorylation and inhibition of angiogenesis. J Urol 169(4):504, 2003.
- Kamat AM, Karashima T, Davis DW, Dinney CPN, McConkey DJ. The proteasome inhibitor PS-341 sensitizes drug-refractory human transitional cell tumors to gemcitabine. J Urol 169(4):495, 2003.
- Kamat AM, Riggs DR, Lamm DL. Retrovirus mediated suicide gene therapy protects against tumor rechallenge in a murine bladder cancer model (MBT2). J Urol 163(4):118, 2000.
- Kamat AM, DeHaven JI, Riggs DR, Pathak VK, Hu WS, Lamm DL. Suicide gene therapy for bladder cancer using retrovirus mediated delivery in a murine model. J Urol 64(4):119, 1999.
- Kamat AM, DeHaven JI, Lamm DL. Cytotoxic effect of Nerium oleander extract on bladder cancer cells. J Urol 161(4):115, 1999.
- DeHaven JI, Anderson MI, Kamat AM, Riggs DR, Hogan TF, Lamm DL. Combined and sequential paclitaxel-based chemosensitivity in renal cell adenocarcinoma cell lines. ASCO Program Proceedings, 1999.
Book Chapters
- Williams SB & Kamat AM. Urothelial Carcinoma with Variant Histology: Sarcomatoid, Plasmacytoid, and Micropapillary. In: Rare Genitourinary Tumors. Springer, 2016.
- Abel EJ, Kamat AM. Bladder Cancer. In: Atlas of Bladder Cancer. Springer: New York, 221, 2010.
- Kamat AM, Nseyo UO. Dysuria. In: Five Minute Urology Consult. Lippincott: Philadelphia, 28-29, 2000.
- Kamat AM. Laboratory investigation in urology. In: Urology for Primary Care Physicians. WB Saunders, 23-31, 1999.
Letters to the Editor
- Li R, Sylvester R, Dinney CP, Kamat AM. Letter to the Editor: Bacillus Calmette-Guerin (BCG) Treatment Failures with Non-Muscle Invasive Bladder Cancer: A Data-Driven Definition for BCG Unresponsive Disease. Bladder Cancer 3: 147-148, 2017.
- Amrhein J, Kamat AM, Morales A. Re: Jarow JP et al.: Clinical trial design for the development of new therapies for non-muscle-invasive bladder cancer: report of a Food and Drug Administration and American Urological Association public workshop (Urology 2014;83:262-265). Urology 84: 494-5, 2014.
Grant & Contract Support
Title: | GU SPORE Project 2 - Role of MicroRNA in Bladder Cancer Risk and Outcome: A genome-wide |
Funding Source: | NIH/NCI |
Role: | Clinical Co-Leader |
Title: | Identifying Surrogate Markers of Treatment Response to Intravesical Immunotherapy for Bladder Cancer |
Funding Source: | FAMRI |
Role: | Principal Investigator |
Title: | GU SPORE - Project 1 Targeting FGFR and EGFR in bladder cancer |
Funding Source: | NIH/NCI |
Role: | Collaborator |
Title: | A Phase III, Open Label Study to Evaluate the Safety and Efficacy of INSTILADRIN? (rAd-IFN/Syn3) Administered Intravesically to Patients with High Grade, BCG Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC) |
Funding Source: | FKD Therapies Oy |
Role: | Principal Investigator |